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ABSTRACT 
 
The objective of this work was to describe the current epidemiology, evaluate the short and 
long-term prognosis and test novel strategies to treat infections in cirrhotic patients 
Methods  
We conducted four studies using two different cohort of cirrhotic patients collected 
prospectively and developing bloodstream infections (BSIs) at 19 centers from September-
2014 to December-2015 (BICHROME) and all consecutive cirrhotic patients admitted for an 
episode of acute decompensation from January-2014 to March-2016 at S.Orsola-Malpighi 
Hospital, Bologna and at the “Infermi” Hospital, Rimini(BIC). 
Results  
The BICHROME study included 312 patients. Gram-negative bacteria, Gram-positive cocci 
(GPC) and Candida spp. caused 53%, 47% and 7% of episodes, respectively. At 
multivariate analysis factors independently associated to GPC isolation were alcoholic 
cirrhosis (p=0.03), device-related infection (p=0.007), pneumonia (p=0.02), previous 
hepatorenal syndrome (p=0.03) and diabetes with organ damage (p=0.008) 
The 30-day mortality rate was 25% and best predicted by the CLIF-SOFA score (aROC 
0.82). In a Cox-regression model, delayed (>24h) antibiotic treatment (p<0.001), inadequate 
empirical therapy(p<0.001) and CLIF-SOFA(p<0.001) were predictors of 30-day mortality. 
Among patients receiving adequate treatment with piperacillin-tazobactam or carbapenems, 
those receiving continuous or extended infusion of such antibiotics showed a significantly 
lower mortality rate even after adjusting for cofounding factors(p=0.04).  
In the BIC study, among the 516 patients enrolled, 32% presented an infection. Multivariate 
logistic regression showed that MELD-Na (p=0.001), QuickSOFA (p=0.004), bacteremia 
(p=0.004) and isolation MDR pathogens (p=0.048) were independent predictors of acute-
on-chronic liver failure(ACLF). Kaplan-Meyers curves showed that 1-year survival was 
similar in infected and non-infected patients without ACLF (71% vs 67%,p=0.337). As 
expected, 1-year survival was worsened by the presence of ACLF.  
Conclusion  
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With this work we explored the current epidemiology of bacterial infection in cirrhotic 
patients, we identified risk factors for MDR pathogens and for BSI caused by GPC. We also 
assessed long-term prognosis of infection complicated or non-complicated by ACLF.  
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INTRODUCTION  
 
Liver cirrhosis is the 10th most common cause of death in Western world (1). Among the 
complications of the end-stage liver disease (ESLD), infection represents the leading cause 
of acute decompensation (2, 3) and is associated with a high mortality ranging from 12% to 
52% (4, 5).  
Despite these patients are particularly prone to develop bacterial and fungal infections(6), 
the cirrhosis of the liver is not commonly considered a major immunodepressive condition. 
However, patients with ESLD exhibit an important impairment of immune system. This 
condition, called cirrhosis-associated immune dysfunction(CAID) summarizes both local and 
systemic immune system alterations in liver cirrhosis that play a pivotal role in determining 
both the high incidence of infections and the ominous infections related mortality in this 
patient population (7, 8). Overall mortality of infected cirrhotic patients in around 30% at 1 
month and more than 50% at 12 months (8). The high mortality rate of infections in cirrhotic 
patients is related not only to the direct effects of infections but, above all, to their pivotal 
role in triggering the condition of acute-on-chronic liver failure (ACLF).  For this reason, 
infection is considered an important prognostic marker in patients with ESLD. 
 Another concerning feature of infections in cirrhotic patients is the growing prevalence of  
multidrug-resistant (MDR) or extensively drug-resistant (XDR) pathogens, which are 
associated with higher mortality, increased length of in-hospital stay and higher healthcare 
related costs if compared with infection caused by susceptible strains (9-11). In addition to 
these clinical features, the threat of MDR/XDR pathogens relies on their ability to rapidly 
spread to patients in absence of contact precautions. As a consequence, an important 
transmission of MDR gram-negative bacilli between patients is observed during 
outbreaks(12).  
 
In this setting a multifaced approach is needed to face all the management challenges 
offered by patients with ESLD with infection. This include the knowledge of contemporary 
epidemiology, the development of prognostic tools and the testing of novel therapeutic 
strategies.   
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Epidemiology of bacterial infection in patients with liver cirrhosis   
 
In light of the emerging threat of multidrug-resistant organisms (MDRO), mainly related the 
ominous spread of extended-spectrum beta-lactamase producing (ESBL) and carbapenem-
resistant Enterobacteriaceae (CRE) and carbapenem resistant non-fermenting bacilli in the 
last decade, an increasing number of epidemiological studies were recently published. To 
better understand the evolution of epidemiology of bacterial and fungal infections in this 
setting the most representative studies are summarized in the table 1.  
 
Table 1. Summary of epidemiological studies on patients with liver cirrhosis. Only 
studies including all different source of infection are reported 
Studies published in the 90’ 
Author/year/ 
Geographic 
area (ref) 
Populatio
n  
Most representative source of 
infection  
Etiology (prevalence of MDRO) 
SBP UTI LRTI Primary 
BSI  
Gram-
negative 
Gram-
positive 
Fungi 
Caly/1993/ 
Brazil(13) 
All 
cirrhotics 
31% 25% 25% NR 72%(NR) 28% NR 
Toledo/1994/ 
Spain(14) 
All 
cirrhotics 
44% 26% 10% 5% 65% (61% 
E.coli) 
39% NR 
         
Studies published from 2000 to 2015 
Author/year/ 
Geographic 
area (ref) 
Populatio
n 
Most representative source of 
infection  
Etiology (prevalence of MDRO)   
SBP UTI  LRTI Primary 
BSI  
Gram-
positive 
Gram-
negative 
Fungi 
Borzio/2001/ 
Italy (15) 
All 
cirrhotics 
23% 41% 17% 21% 46% 49% 4% 
Rosa/2000/ 
Brazil (16) 
All 
cirrhotics 
54% 7% 18% NR NR NR NR 
Fernandez/ 
2002/Spain (17) 
All 
cirrhotics 
24% 19% 13% 5% 45% 47% NR 
Fernandez(201
2)/Spain(4)/ 
first series  
All 
cirrhotics 
56% 43% 20% 13% 44% 
(MRSA 
3% of all 
infections) 
46% 
(ESBL 9% 
of all 
infections)  
NR 
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Fernandez/201
2/Spain(4)/ 
second series 
All 
cirrhotics 
20% 25% 13% 13% MRSA 7% 
of all 
infections 
ESBL 7% of 
all 
infections 
NR 
Studies published from 2015 to 2017 
Author/year/ 
Geographic 
area (ref) 
Populatio
n 
Most representative source of 
infection  
Etiology (prevalence of MDRO)  
SBP  UTI  LRTI Primary 
BSI  
Gram-
positive 
Gram-
negative 
Candida 
spp 
Merli/2015/ 
Italy(9) 
All 
cirrhotics 
8% 61% 12% 6% 47% 47% NR 
Park/2015/ 
Korea (18) 
Alcoholic 
liver 
disease 
9% 4% 38% 4% 35% 
(MRSA 
86%)  
63% (ESBL 
in 42% of 
Enterobact
eriaceae) 
2% 
Dionigi/2017 
/England (19) 
All 
cirrhotics  
42% 19% 9% 28% 58% 
(MRSA 
18%) 
41% (ESBL 
20% of 
GNB) 
NR 
Salerno/2017 
Italy and 
England (20) 
All 
cirrhotics 
18% 43% 7% 17% 58% 
(MRSA 
51%) 
47% (44% 
ESBL 
production 
,9% CR-
GNB  
3% 
Piano/2017/  
Italy(21) 
All 
cirrhotics 
33% 23% 14% 13% 46% 47% 7% 
    
The wide variability in term of site of infection and causative pathogens is mainly related to 
several factors. First, with exception of SBP, there is no agreement for most of infection 
definitions and most studies did not adopted the widely agreed criteria for infection diagnosis 
used in non-cirrhotic population. Second, the epidemiology of infection is currently under 
constant evolution and may vary between centres. Third, similarly to the previous point, 
different study site may be characterized by different level of commitment in the 
management of cirrhotic patients. Thus, tertiary sites with dedicated liver unit and access to 
a transplantation program may exhibit a population with more advanced stage of liver 
disease if compared with urban hospitals. Despite inhomogeneity, these studies clearly 
show that the rate of MDRO has increased dramatically and the improvement of the 
management of liver cirrhosis may have changed also the characteristics of infection site. 
In fact, in the studies published in the 90’ and in the first years of the 21th Century the 
diagnosis of SBP was prevalent (24-56% of case). Conversely latter studies report a lower 
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prevalence of SBP (8-18%, excluding one paper that included bacteriascites in the definition 
of SBP and reported 42% of such infection) and higher rate of bloodstream infection (6-28%) 
and pneumonia (7-38%).  
Few studies reported to date differences in the kind of infection and in the causative 
pathogens in patients with alcoholic liver disease (ALD) and patients with other causes of 
liver cirrhosis. Previous studies on BSI including mainly patients with alcoholic cirrhosis 
report a higher prevalence of gram-positive cocci (GPC) among the different etiologies of 
BSI. However most of these studies are old or characterized by a single-center design(22, 
23). In addition, infection in alcoholic cirrhosis seems to be characterized by higher 
frequency of ACLF, however conflicting results on the outcome are reported(3, 24)             
 
 
Risk factors for multidrug-resistant pathogens 
To date few studies evaluated risk factors for MDRO in the setting of cirrhosis (table 2).  
 
Table 2 Risk factors for multidrug-resistant pathogens in patients with liver cirrhosis 
and infection 
AUTHOR/YEAR/ 
GEOGRAPHC 
AREA (REF)  
KIND OF 
INFECTIONS 
PREVALENCE AND KIND OF 
MDRO 
RISK FACTORS  
Merli/2015/ 
Italy (9) 
All bacterial 
infections 
51% • Antibiotic prophylaxis  
• HA or HCA infections 
Kim/2013/ 
Korea(25) 
Community-
onset SBP 
32% of FQ resistant E. coli • FQ use (30dd)  
• Previous SBP episode 
• Third-generation 
cephalosporin 
resistance 
Fernandez/2012/ 
Spain(4)/ 
first series 
All bacterial 
infections 
 • Nosocomial origin of 
infection   
• Long-term norfloxacin 
prophylaxis 
• Recent infection by 
multi-resistant bacteria   
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• Recent use of b-
lactams 
Chaulk/2013/ 
Canada(26) 
SBP 19% third-generation 
cephalosporin resistance  
• Nosocomial 
acquisition of infection  
Song/2009/ 
Korea (27) 
SBP 7% ESBL-Enterobacteriaceae • Nosocomial 
acquisition 
• Previous SBP episode 
Alexopolu/2012/ 
Greece(28)  
SBP 24% • MELD score 
• HCA 
• Quinolone prophylaxis 
Ariza/2012/ 
Spain(29) 
HA and HCA 
SBP  
 
42% third generation 
cephalosporine resistance of 
HA SBP 
• Diabetes mellitus 
• Upper GI bleeding 
• Hospital acquired  
• Previous 3rd Gen 
Cephalosporine use 
  
  
Most of the reported studies focused on SBP whereas only 2 studies included all various 
sources of infection. The most reported risk factors for MDR were antibiotic exposure 
(antibiotic prophylaxis, use of third generation cephalosporines, fluoroquinolones or beta-
lactams) and exposure to healthcare environment (i.e. hospital-acquired or healthcare 
associated infections, previous hospital admission).    
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Infection related ACLF and prognosis  
As mentioned before the high mortality rate of infections in cirrhotic patients is related not 
only to the direct effects of infections but, above all, to their pivotal role in triggering the 
condition of acute-on-chronic liver failure. In a prospective multicenter study (CANONIC 
study), bacterial infection was found to be the precipitating event of ACLF in 32% of 
cases(30). A further analysis of the CANONIC study revealed that bloodstream infections, 
pneumonia and SBP are more likely to be associated with ACLF. In addition, in patients with 
ACLF grade I and II, the presence of bacterial or fungal infection was associated with worse 
outcome. Similarly, single-center study, among patients with ACLF, infection was a risk 
factor for 30-day. Despite these findings, a better understanding of the interaction between 
bacterial infection and ACLF is needed. In fact, the specific role of different kind of infections 
in determining ACLF and its risk factors are not clearly established.  
Infection is considered an important prognostic marker in patients with ESLD.  In a in a large 
multicenter cohort of patients with biopsy-proven compensated viral cirrhosis, the 
occurrence of a bacterial infection impaired survival both in patients HCV-infected (5-year 
survival: 60.2% vs 90.4%, p<0.001) and HBV-Infected (5-year survival: 69.2% vs 97.6%, 
p<0.001), representing the third cause of death (14.1%) after liver failure and liver cancer. 
Similarly, in a single-center study enrolling 501 patients, bacterial infection was 
independently associated to mortality. The authors concluded that bacterial infection 
represents a different stage of the disease, which affect survival, even after recovery form 
an infectious episode (19). Despite the finding that bacterial infection is a marker of poor 
prognosis seems clearly established, several aspects are worth to be deeply investigated. 
In fact, the role of different kind of infections are yet to be established.  
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Antimicrobial Pharmacokinetics/ Pharmacodynamic issues in liver cirrhosis 
Ensuring a prompt and appropriate empirical antimicrobial treatment for infections in liver 
cirrhosis is essential in LC. (31, 32) 
The concept of appropriateness for empirical and targeted antimicrobial treatment relies on 
a right antimicrobial coverage associated to an appropriate exposure consistent with the 
drugs’ pharmacokinetic-pharmacodynamic (PK/PD) features.  Pharmacokinetic variability is 
a major contributor to therapeutic failure: therefore to guarantee a correct exposure to 
antibiotics, timely administration of the right dose at the right schedule, according to the 
pathophysiological and immunological status of the patient, is required. (33) 
Patient with LC have several unique pathophysiological characteristics that can alter the 
PK/PD behavior and the in vivo activity of antimicrobial agents. These characteristics 
include: i) hypoalbuminemia and reduction binding to proteins; ii) altered distribution; iii) 
altered clearance of the antimicrobial. (34) 
The reduction of antimicrobial protein binding is a consequence of decreased albumin 
production and accumulation of antibiotic binding inhibitors (such as bilirubin or α-acid 
glycoprotein) in patients with LC.(34) Depending on the degree of antibiotic protein binding, 
patients with LC may have, both in plasma and tissues, a higher fraction of unbound drug. 
This is the microbiologically active drug, but also the fraction that is cleared more rapidly 
through renal or hepatic pathways. Hence, patients with hypoalbuminemia have a higher 
proportion of drug “escaping” from the bloodstream and distributing into tissues, translating 
to increased distribution volume (Vd) and reduced or sometimes sub-therapeutic 
bloodstream concentrations required to treat severe infection. (35, 36)  
In patients with advanced LC, splanchnic congestion and fluid retention due to 
hypoalbuminemia and reduced renal blood flow can further increase the Vd for relatively 
hydrophilic antibiotics, such as beta-lactams, aminoglycosides, and vancomycin. As a result, 
most of the patients with ACLF presents with oedema, ascites and third space expansion 
resulting in inadequate blood levels of these antibiotics. (36, 37) Therefore larger loading 
and daily doses and are often required for hydrophilic antibiotics to achieve therapeutic 
blood levels.   
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On the other hand, increased Vd may also prolong the drug elimination irrespective of the 
clearance rates. (35) In some patients with LC, antibiotics half-life is increased, paradoxically 
causing drug accumulation and potential for toxicity. (38) 
Finally, the PK of antibiotics can be affected by liver-disease related changes in renal 
function that are very common in this population. Renal failure in LC is mainly due to a 
reduced renal perfusion secondary to a vasodilatation in the splanchnic circulation without 
a compensation of cardiac output.(39) Although clearance of creatinine is widely accepted 
as a viable method for renal function assessment, several studies demonstrate that 
measured creatinine clearance from timed urine collection may overestimate the glomerular 
filtration rate in LC even in patients without hepatorenal syndrome. (40) 
Unfortunately, antibiotic PK/PD is rarely studied in patients with liver dysfunction, especially 
in patients with advanced cirrhosis and ascites (i.e. Child-Pugh Class C). This kind of 
patients are commonly excluded form phase 1, phase 2 and phase 3 studies.  Consequently, 
there is currently little or no scientific basis for antibiotic doses currently administered to treat 
life-threatening infections in patients with advanced cirrhosis.  Given the unpredictable drug 
exposure, therapeutic drug monitoring (TDM) might play a pivotal role for individualizing 
doses, both in lowering exposure-dependent toxicity and in ensuring an optimal drug 
exposure, especially for the treatment of serious infections or MDR pathogens.  
Beta-lactams are commonly used and represent the first-line therapy of most infection in 
patients with liver cirrhosis(41). Beta-lactams are time-depending drugs which ensure the 
best effectiveness with a prolonged time of exposure above the pathogen minimal inhibitory 
concentration (T>MIC)(42).  Previous studies in general population indicate that continuous 
or extended infusion of beta-lactams is associated to better drug exposure and higher 
T>MIC and consequently better outcome for severe infection(43).  
According with the aforementioned pathophysiological characteristics, the cirrhotic patient 
seems an important setting to test continuous infusion of beta-lactams for treating severe 
infections.  
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OBJECTIVES OF THIS THESIS  
The present thesis comprises 4 different studies.   
The objectives of the studies are hereby reported:  
1. Bloodstream infection in cirrhotic patients: an exploratory prospective 
multicenter study (study already published:  Bartoletti M, Giannella M, Lewis R, 
Caraceni P, Tedeschi S, Paul M, et al. A prospective multicentre study of the 
epidemiology and outcomes of bloodstream infection in cirrhotic patients. 
Clinical microbiology and infection: the official publication of the European 
Society of Clinical Microbiology and Infectious Diseases. 2017. Epub 
2017/08/19.)  
• Describe the current epidemiology of BSI in patients with liver cirrhosis 
in a large multicenter study  
• Assess the best predictors of 30-day mortality in cirrhotic patients with 
BSI  
• Find universal risk factors for MDRO in cirrhotic patients with BSI  
2. Continuous infusion of beta-lactam antibiotics in cirrhotic patients with 
bloodstream infection: results from a prospective multicenter observational 
study 
• Assess the effectiveness of continuous or extended infusion of beta-
lactams in cirrhotic patients with BSI  
3. Differences in the etiology and outcome of bloodstream infection in patients 
with alcohol-related liver cirrhosis and non-alcoholic liver cirrhosis: results 
form a prospective multicenter study.   
• Describe differences in the severity, source and outcome in patients 
with alcoholic liver disease and cirrhosis secondary to other conditions  
• Find risk factors for BSI caused by GPC 
4. Epidemiology of acute-on-chronic liver failure associated with bacterial 
infection in patients with liver cirrhosis: risk factors and outcome 
15 
 
• Find risk factors for ALCF in patients with any bacterial infection or 
fungal infection  
• Describe the long-term outcome of patients with or without bacterial or 
fungal infection complicated or non-complicated with ACLF.  
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STUDY 1. BLOODSTREAM INFECTION IN CIRRHOTIC PATIENTS: AN EXPLORATORY 
PROSPECTIVE MULTICENTER STUDY 
METHODS 
 
 
Study design  
 
We performed an exploratory prospective, multicentre, observational cohort study with the 
endorsement of European Study Group of Bloodstream infections and Sepsis (ESGBIS). 
The ESGBIS members who agreed to participate were asked to report all consecutive 
patients with liver cirrhosis who developed a BSI, from September 2014 to December 2015. 
The study was approved by all local institutional review board in participating hospitals. 
Written informed consent was obtained from patients or from legal surrogates before 
enrolment.  
 
 
Population   
 
All adult (>18 years) patients with liver cirrhosis developing BSI were included in the study. 
The diagnosis of liver cirrhosis was based on previous liver biopsy results or a composite of 
clinical signs and findings provided by laboratory test results, endoscopy and radiologic 
imaging.(3)  
Bloodstream infection was defined the growth of a non-common skin contaminant from ≥ 1 
blood culture (BC) and of a common skin contaminant such as diphtheroids, Bacillus 
species, Propionibacterium species, coagulase negative staphylococci (CoNS), or 
micrococci from ≥ 2 BCs drawn on separate sites and reporting the same antimicrobial 
susceptibility test profile.  
Patients with previous liver transplantation were excluded. Patients with subsequent 
episodes of BSI with an interval between BSIs lower than 3 months were excluded. Patients 
were followed-up to 30 days after the BSI onset. This latter was set at the day of blood 
cultures collection.  
Data collection 
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Data were collected using an electronic case report form available at the study web site. The 
integrity of data was systematically checked by an investigator before being entered into the 
database by a monthly assessment of data completeness and consistency. In case of 
inconsistent or missing data, queries were generated and distributed to the participating 
site’s investigators for reconciliation. The following variables were collected at the moment 
of enrolment using patient’s medical records: demographic variables (sex, age); the cause 
and severity of liver disease according with the baseline model for end-stage liver disease 
(MELD); presence of hepatocellular carcinoma (HCC);  presence of other co-morbidities 
according with the Charlson score(44); invasive procedure performed within 30 days before 
BSI onset were collected: gastrointestinal endoscopy including 
esophagogastroduodenoscopy, colonoscopy, endoscopic retrograde 
cholangiopancreatography, endoscopic ultrasound; transjugular intrahepatic portosystemic 
shunt (TIPS) insertion; biliary procedures including biliary percutaneous drainage and/or 
stenting; HCC treatments; date, ward and cause of hospitalization; epidemiological 
classification of BSI; infection severity according with Bone’s score(45), sequential organ 
failure assessment (SOFA), chronic liver failure-SOFA (CLIF-SOFA) and MELD scores 
calculated at the day of drawing the positive  BCs;  pathogens isolated and their susceptibility 
patterns; antibiotics administered as empirical therapy and that as definitive therapy. 
Outcome variables were collected after 30 days from BSI onset during either bed-side 
evaluation, outpatient visit, or telephone call. These included the need of intensive care unit 
(ICU) admission, length of in-hospital stay and 30-day transplant-free mortality.  
 
 
Definitions  
 
MELD was calculated at the time of index BC (BSI-MELD) as previously described.(46) 
Baseline MELD was defined as the most recent MELD within 2 weeks prior BC drawn. The 
patient had to be free from symptoms of infection and/or acute decompensation. Δ- MELD 
was defined as the difference between BSI-MELD and baseline MELD. 
Primary BSI was defined as the laboratory confirmed BSI that is not secondary to an 
infection at another body site after comprehensive screening with clinical findings, laboratory 
test (e.g. urine analysis, peritoneal fluid cell count) and radiological imaging (chest X-rays 
or computed tomography scan, abdomen echography). Source of secondary BSI was 
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defined according with Centres for Diseases Control and Prevention criteria(47), in addition: 
spontaneous bacterial peritonitis (SBP) was deemed as the source of BSI when the same 
organism is isolated form BC and peritoneal fluid, in presence of ≥ 250 polymorphonuclear 
cells/ml of fluid without other evident infection sources;(48) TIPS related BSI was defined as 
persistent (positive BC after ≥ 7 days despite adequate antimicrobial treatment)  or relapse 
(growth of the same organism as in the original BC after the end of therapy but before day 
30) bacteraemia in a patient with TIPS and no other known source of infection after a 
comprehensive diagnostic work-up.(49)  
Sepsis grading was assessed with SOFA(50) and Bone’s criteria. Sepsis was defined by at 
least 2 of the following: temperature >38C or <36°C, respiratory rate >20 or PaCO2 <32 
mmHg, heart rate >90, altered mental status, systolic blood pressure <90 mmHg, leukocyte 
count >12.000/mm3, or <4,000/mm3 or immature forms >10%. Severe sepsis was defined 
as sepsis plus sepsis-induced organ dysfunction or tissue hypoperfusion; septic shock was 
defined as sepsis-induced hypotension persisting despite adequate fluid resuscitation(45). 
CLIF-SOFA was calculated as described by Moreau et al.(3) Organ failures were assessed 
according with the following criteria: liver failure was defined by a serum bilirubin level of 
≥12.0 mg/dL; kidney failure was defined by a serum creatinine level of ≥ 2.0 mg/dL or the 
use of renal replacement therapy; cerebral failure was defined by grade III or IV hepatic 
encephalopathy, according to the West Haven classification; coagulation failure was defined 
by an international normalized ratio 2.5 and/or a platelet count of <20 X109/L; circulatory 
failure was defined by the use of dopamine, dobutamine, or terlipressin.  
Acute-on-chronic liver failure (ACLF) was diagnosed and classified as previously 
described.(3) Patients were classified as having : i) hospital acquired BSI if infection 
signs/symptoms started >48 hours after hospital admission, or in less than 48 hours after 
hospital discharge; ii) healthcare-associated BSI if they acquired bacteraemia outside the 
hospital but fulfilled any of the following criteria: prior hospitalization for ≥2 days or surgery 
in the past 90 days, residence in a nursing home or long-term care facility, intravenous 
therapy, wound care or specialized nursing care at home in the past 30 days, chemotherapy 
in the past 30 days and chronic haemodialysis; iii) community acquired BSI was defined for 
any other case.(51) 
Gram-negative were classified as multidrug-resistant (MDR) according to the European 
Society of Clinical Microbiology and Infectious Diseases consensus definitions.(52) As for 
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Gram-positive bacteria: methicillin-resistant Staphylococcus aureus (MRSA), methicillin-
resistant CoNS and Enterococcus faecium were classified as MDR.  
Empirical therapy, defined as treatment administration before the susceptibility tests were 
available, was considered as adequate when at least one antibiotic was active in vitro 
against the isolated pathogen and was administered within 24 hours after index BCs, at 
recommended dosages according with pharmacokinetic / pharmacodynamic drug properties 
for non-cirrhotic patients.(33, 36) Definitive therapy, treatment administration according with 
the susceptibility results, was considered as adequate when an active antimicrobial regimen, 
adjusted according to microbiological results, was administered until the end of antibiotic 
course (for at least 48 h). 
 
 
Microbiology  
 
Before study onset, the use of standard diagnostic methods was required and agreed with 
all the participating centres. They include at least the use of an automated detector system, 
the performance of Gram stain and/or rapid test (such as MALDI-TOF, PNA FISH) with 
immediate communication of the preliminary information to the attending physicians, the use 
of an automated system (Vitek n=17, MicroScan n=2) for susceptibility testing. Breakpoints, 
screening and conformation of the main mechanisms of resistance were done according 
with EUCAST guidelines.(53) 
 
 
Statistical analysis  
 
Categorical variables were presented as absolute numbers and their relative frequencies 
and were compared using the chi-square test.  Quantitative variables were presented as 
mean and standard deviation (SD) if normally distributed or as median and interquartile 
range (IQR) if non-normally distributed. Non-normally distributed continuous variables were 
compared using the Mann-Whitney U test, normally distributed continuous variables were 
compared using the t test.  
Analysis of predictors of mortality  
The discrimination of six established mortality risk scores for all-cause 30-day mortality were 
analyzed calculating the area under the receiver operator curve (aROC).  Risk scores with 
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the highest aROC were then evaluated in a multivariate Cox-regression model to identify 
the risk score with the best overall fit (Akaike information criterion) and discrimination 
(Harrell’s C statistic) for 30-day all-cause mortality. Finally, factors associated (P<.1) to 30-
mortality in the univariate analysis entered in a Cox-regression model including the best risk 
score previously identified. All variables were explored for interaction and collinearity. The 
impact of infection-related or treatment variables was assessed at three levels of baseline 
risk (low, medium and high) determined by classification-regression-tree (CART) analysis. 
Martingale residuals from the Cox model were used to calculate Chi-square values at all 
score cutpoints at P<.05.  
The strength of association between specific pathogen resistance profiles and the 
inadequate antimicrobial therapy were analyzed using the Spearman’s rank correlation 
coefficient and plotted as weighted bubble plot by pathogen prevalence. 
Analysis of risk factors for MDRO  
To assess the independent risk factors for MDRO isolation, all the variables with a p value 
≤.10 at the univariate analysis were included in a forward, conditional stepwise multivariate 
logistic regression model. The validity of the final model was assessed by estimating 
goodness-of-fit to the data with the Hosmer-Lemeshow test.  
All analysis was performed with Stata IC 13 (Stata Corp, College Station, Texas). 
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RESULTS 
 
 
Patients recruitment and baseline characteristics  
 
Nineteen of the 25 invited centres agreed to participate. Participating hospitals were all 
tertiary teaching facilities from Italy (10 centres), Spain (5 centres), Germany (2 centres), 
Croatia (1 centre) and Israel (1 centre). 
A total of 323 patients were enrolled in the study. Excluded patients had incomplete data (7 
cases), had a single BSI caused by CoNS (2 cases) or were recipient of liver transplant (2 
cases). Thus, 312 patients were analysed (fugure 1). 
 
 
Figure 1 Study flow-chart 
 
Overall, 204 (65%) were male, mean (±SD) age was 61(±12) years. Alcohol abuse and HCV 
infection were the cause of cirrhosis in the 40% and 36% of cases, respectively. The most 
common reasons for hospital admission were suspected bacterial infection (42%), acute 
decompensation non-related to bacterial infection (40%), or scheduled procedures (6%) 
(Table 3).   
BSIs were classified as primary 99 (32%), catheter related 32 (10%) and secondary 181 
(58%). Secondary BSIs included: intra-abdominal sources (99, 32%), mostly represented by 
SBP (50/99 50%) and cholangitis (26/99, 26%); urinary tract (35, 11%); lower respiratory 
tract (19, 6%); and others including endocarditis (11, 3%), skin and soft tissues (10, 3%), 
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TIPS (5, 2%), bone and joint infections (4, 1%) and surgical sites (4, 1%). Six patients had 
multiple sources reported for their BSI.  
 
 
Thirty-day mortality 
 
At the end of 30-day follow-up, 79/312 (25%) patients died. According with BSI source, SBP 
(18/50, 36%) and pneumonia (6/19, 31%), showed the highest mortality, together with 
primary BSI (30/99, 29%). Comparison of survivors and non-survivors showed that patients 
with worse outcome were more likely to be admitted for non-infectious causes, such as 
hepatic encephalopathy and hepato-renal syndrome. In addition, at BSI diagnosis non-
survivors had more frequently ACLF, septic shock, higher CLIF-SOFA and higher Δ-MELD 
(table 3) 
.      
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Table 3.  Characteristics of the entire cohort. Difference of underlying conditions, BSI 
data and therapeutic management between survivors and non-survivors. 
 TOTAL, 
N=312 
(100%) 
NON-
SURVIVORS, 
N=79 
(25%) 
SURVIVORS  
N=233 
(75%) 
P 
Demographic data     
   Age (years) [mean (± SD)] 61 (±12) 60 (±10) 62 (± 12) .26 
   Male sex  204 (65) 52 (65) 152 (65) .92 
Liver disease a     
Hepatitis C  112 (36) 27 (34) 85 (36) .71 
Alcoholic 125 (40) 32 (41) 93 (40) .96 
 Hepatocellular carcinoma 50 (16) 11 (14) 39 (16) .72 
Baseline MELD 15 (11-20) 18 (14-21) 14 (10-19) .01 
Admission diagnosis     
   Ascitic decompensation 44 (14) 13 (16) 31 (13) .48 
   Hepato-renal syndrome 14 (4) 7 (9) 7 (3) .05 
Hepatic encephalopathy 29 (9) 13 (16) 12 (5) .01 
Bacterial infection  131 (42) 20 (25) 111 (48) .01 
Co-morbidities     
Charlson index [mean (± SD)] 7 (±3) 7 (±3) 7 (±3) .81 
BSI data     
Site of infection acquisition     
Community-acquired BSI 60 (19) 12 (15) 48 (21) .29 
Hospital-acquired BSI 170 (54)  50(63) 120 (51) .06 
Healthcare associated   82 (26) 17 (21) 65 (28) .30 
Primary 99 (32) 30 (38) 70 (30) .19 
SBP 50 (16) 18 (23) 32 (13) .05 
Urinary tract 35 (11) 5 (6) 30 (13) .09 
Infection severity      
   ACLF 113 (36) 59 (74) 54 (23) <.001 
   CLIF-SOFA score [median (IQR)] 6 (4-9) 10 (7-15) 5 (3-7) <.001 
MELD at BSI [median (IQR)] 18 (12-24) 26 (21-31) 16 (12-20) <.001 
∆ MELD (at BSI - baseline) [median 
(IQR)] 
2 (0-5) 5 (2-10) 1 (0-4) <.001 
   Severe sepsis 45 (14) 16 (20) 29 (12) .10 
   Septic shock 41 (13) 27 (35) 14 (6) <.001 
Therapeutic management     
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Adequate empirical treatment  190 (61) 31 (39) 159 (68) <.001 
   <6h 153 (49) 20 (25) 133 (57) <.001 
   Between 6 and 24h 24 (8) 4 (5) 20 (9) .31 
   >24h 13 (4) 7 (9) 6 (3) .01 
Inadequate 122 (39) 48 (61) 74 (32) <.001 
   ICU admission 84 (27) 39 (50) 45 (19) <.001 
 
Among the different risk scores calculated at the day of BSI onset, CLIF-SOFA (aROC 0.82; 
95% CI 0.78-0.86), SOFA (aROC 0.82¸95% CI 0.77-0.86); MELD (aROC 0.79; 95% CI 0.74-
0.83) and delta MELD (aROC 0.76; 95% CI 0.70-0.84) showed roughly equivalent 
discriminative performance for 30-day all-cause mortality (Figure 2A). In contrast, 30-day 
mortality probability related to sepsis grading (aROC 0.58; 95% CI 0.53-0.64) and Charlson 
co-morbidity index (aROC 0.52; 0.44-0.61) did not reliably discriminate non-surviving versus 
surviving patients with liver cirrhosis and BSI at 30 days. 
In the Cox-regression model, CLIF-SOFA was associated with the lowest Akaike information 
criterion (AIC) score (768.07) and Harrell’s C index (0.80) followed by BSI-MELD (AIC 798; 
Harrell’s C 0.76). Therefore, risk factors for poor survival identified in univariate analysis 
(P<.1) related to admission diagnosis, epidemiological classification of BSI, presence of 
sepsis or septic shock and timing and adequacy of antimicrobial therapy were entered into 
multivariate Cox-regression model with patients CLIF-SOFA score as a continuous variable. 
Severity of sepsis displayed a collinearity with CLIF-SOFA scores and was not retained in 
the final model. Delayed (>24h) empirical treatment [HR 7.58 (95% CI 3.29-18.67), 
P<.0001], inadequate empirical treatment [HR 3.14 (95% CI 1.93-5.12), P<.0001] and CLIF-
SOFA [HR 1.35 (95% CI 1.28-1.43), P<.0001] were independently associated with 
increased 30-day mortality. Admission to the hospital with a diagnosis of bacterial infection 
was associated with a lower 30-day mortality [HR 0.58 (95% CI 0.35-0.97), P<.04]. Exclusion 
of admission diagnosis was associated with a modest reduction in the AIC (752 vs. 753). 
Therefore, the most parsimonious model for 30-day mortality included only CLIF-SOFA, 
inadequate empirical treatment and delayed empirical treatment > 24 hours. After 
stratification for CLIF-SOFA using CART analysis (Figure 2B), the impact of adequate 
empirical therapy administered within and after 24 hours was evident in patients with low, 
medium and high-baseline risk for mortality (Figure 2C and 2D).  
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Figure 2. Relationship of mortality risk models and 30-day all-cause mortality. (a) comparison of risk 
score discrimination for 30-day mortality. (b) CART-defined cutpoints for CLIF-SOFA score analysis 
for failure time data. Martingale residuals of a Cox model were used to calculate chi square values for 
all possible cutpoints on all the CART covariates at P<.05, N=numbers of patients; F=numbers of 
failures, and RHR=relative hazard ratio; (c) Cox-regression survival estimates of patients receiving 
adequate empirical antimicrobial therapy within 24 hours stratified by CLIF-SOFA score; (d) Cox-
regression survival estimates of patients who do not receive  adequate empirical antimicrobial therapy 
within 24 hours stratified by CLIF-SOFA score.  MELD model for end-stage liver disease, ACLF acute-
on-chronic liver failure, CLIF-SOFA chronic liver failure-sequential organ failure assessment, SOFA 
sequential organ failure assessment 
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Etiology  
 
Overall, a total of 337 isolates were identified from the 312 BSI episodes (Table 4). Gram-
negative bacteria (GNB) accounted for 164/312 BSIs (53%). Most GNB were 
Enterobacteriaceae (136/164, 83%): Escherichia coli (82/164, 50%), Klebsiella pneumoniae 
(29/164,17%) and Enterobacter spp. (13/164, 8%). Fluoroquinolone-resistance, extended-
spectrum β-lactamase (ESBL) and K. pneumoniae carbapenemase (KPC) production was 
identified in 38%, 33% and 7% of Enterobacteriaceae, respectively. Non-fermenting GNB 
were isolated in 9% of BSI episodes, most of which were Pseudomonas spp. (16/28, 60%). 
Gram-positive bacteria (GPB) were found in 146/312 (47%) BSI episodes. The most 
common isolated species were methicillin-sensitive Staphylococcus aureus (MSSA) 
(40/146, 27%), CoNS (25/146, 17%), Streptococcus spp. (24/146, 16%), Enterococcus 
faecium (22/146, 15%), Enterococcus faecalis (15/146, 10%) and methicillin-resistant S. 
aureus (MRSA) (12/146, 8%).  
Candida species accounted for 7% (21/312) of BSIs. Among the 21 episodes of candidemia 
(9 primary BSI, 7 CR-BSI, 4 BSI secondary to SBP and 1 secondary to endocarditis), the 
majority were caused by Candida albicans (n=13), followed by Candida glabrata (n=3). 
The main causative pathogens in polymicrobial infection were enterococci (46% of cases) 
Enterobacteriaceae (36% of cases, 45% of which MDR), Candida spp. (27% of cases) and 
non-fermenting bacilli (23% of cases).  
Pathogens associated to the highest mortality rate were Carbapenem resistant- 
Enterobacteriaceae (4/9, 44%), Candida spp (9/21, 43%), E. faecium (9/22, 41%), ESBL-
producing Enterobacteriaceae (16/45, 36%), Streptococcus pneumoniae (3/9, 33%) and 
MSSA (13/41, 32%). 
Significant differences were found in the etiology distribution of BSI reported from the 
different countries (Table 4). We also found differences in community acquired, healthcare 
associated infections, as expected (table 5). Lastly etiology of BSI according with source of 
infection is presented in the table 6  
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Table 4. Etiology of 312 BSI in cirrhotic patients. Differences between countries. 
 Total, 
n=312 
episodes 
(100%) 
Italy    
n=149 
episodes 
(47%)  
Spain 
n=67 
episodes 
(21%)   
Germany 
n=57 
episodes  
(18%) 
Israel  
n=36 
episodes  
(11%) 
P 
Gram positive 146 (47) 60 (40) 34 (51) 36 (63) 14 (39) .02* 
Coagulase negative 
staphylococci 
25 (8) 10 (7) 6 (9) 6 (10) 3 (8) .88 
Staphylococcus aureus (MSSA) 41 (13) 13 (9) 8 (12) 16 (26) 4 (11) .02* 
Staphylococcus aureus (MRSA) 12 (4) 7 (5) 4 (6) 0 (0) 1 (3) .39 
Streptococcus spp 24 (8) 7 (5) 9 (13) 3 (5) 3 (8) .003 
Enterococcus faecalis  15 (5) 7 (5) 1 (1) 4 (7) 3 (8) .45 
Enterococcus faecium 22 (7) 11 (7) 1 (1) 9 (16) 1 (3) .02 
Other Gram positivea 8 (3) 3(2) 1 (1) 2 (3) 1 (3) .56 
Gram negative 164 (53) 89 (60) 31 (46) 21 (37) 22 (61) .01* 
Enterobacteriaceae 136 (44) 75 (50) 26 (39) 19 (33) 15 (41) .19 
Escherichia coli 82 (26) 43 (29) 16 (24) 4 (7) 10 (28) .70 
Escherichia coli (FQR) 34 (11) 18 (21) 5 (7) 5 (9) 6 (27) .56 
Escherichia coli (ESBL) 23 (7) 15 (10) 0 (0) 3 (5) 5 (14) .04*§ 
Klebsiella pneumoniae 29 (9) 19 (13) 4 (6) 2 (3) 3 (8) .10 
Klebsiella pneumoniae (FQR) 14 (4) 10 (7) 1 (1) 1 (2) 1 (3) .03 
Klebsiella pneumoniae (ESBL) 15 (5) 10 (7) 2(3) 1 (2) 2 (6) .04 
Klebsiella pneumoniae (CR) 9 (3) 8 (5) 1 (1) 0 (0) 0 (0) .15 
Enterobacter spp  13 (4) 5 (3) 5 (7) 2 (3) 1 (3) .61 
Other enterobactericeae b 15 (5) 10 (6) 1 (2) 2 (3) 2 (6) .48 
Non-fermenters 28 (9) 15 (10) 5 (7) 2 (3) 6 (17) .22 
Pseudomonas aeruginosa 16 (5) 9 (6) 4 (6) 0 (0) 3 (8)  
Acinetobacter baumanii 3 (1) 3 (2) 1 (2) 0 (0) 0 (0)  
Stenotrophomonas maltophilia 4 (1) 3 (2) 0 (0) 0 (0) 1 (3)  
Other non-fermentersc 5 (2) 0 (0) 1 (1) 2 (3) 2 (6)  
Other gram negatived 2 (1) 1 (1) 1 (1) 0 (0) 0 (0)  
Anaerobes 6 (2) 3 (2) 1 (1) 2 (3) 0 (0)  
Fungi       
Candida species 21 (7) 11 (7) 4 (6) 5 (9) 1 (3) .76 
Mixed infections 30 (10) 16 (11) 3 (10) 10 (17) 1 (3) .07 
BSI bloodstream infection, MSSA methicillin-susceptible S.aureus, MRSA methicillin-resistant S. aureus ; 
FQR, fluoroquinolone-resistant; ESBL, extended-spectrum beta-lactamase, CR carbapenem-resistant  
#3 cases of BSI enrolled in Croatia are included only in the summary column (1 case of FQR-Klebsiella 
pneumoniae, 2 cases of Streptococcus spp BSI) 
*P<.01 between Italy and Germany 
§P<.01 between Italy and Spain  
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aEnterococcus raffinosus (n=4), Listeria monocytogenes (n=3), Corynebacterium striatum (n=1)  
bMorganella morganii (n=4), Citrobacter spp (n=3), Klebsiella oxytoca (n=3), Roultella planticola (n=2), Proteus 
mirabilis (n=1), Pantoea agglomerans (n=1)  
cAcinetobacter lwoffii (n=1), Aeromonas veronii (n=1), Pseudomonas alcaligenes (n=1), Pseudomonas stutzeri 
(n=1), Pseudomonas oryzihabitans (n=1) 
dMoraxella catarrhalis (n=1), Haemophilus influenzae (n=1)  
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Table 5. Etiology of 60 community acquired bloodstream infection, 82 healthcare 
associated bloodstream infection, 170 hospital acquired bloodstream infections. 
 Community 
acquired BSI  
N= 60 (19%)  
Healthcare 
associated BSI  
N= 82 (26%)  
Hospital-
acquired 
BSI  
N= 170 (54%)  
P 
Gram-positive 26 (43) 36 (44) 84 (49) .59 
Coagulase negative staphylococci 2 (3) 6 (7) 17 (10) .25 
Staphylococcus aureus (MSSA) 7 (12) 9 (11) 25 (15) .25 
Staphylococcus aureus (MRSA) 1 (2) 4 (5) 7 (4) .59 
Streptococcus spp 13 (22) 4 (5) 7 (4) <.001*# 
Enterococcus faecalis  1 (1) 5 (6) 9 (5) .45 
Enterococcus faecium 1 (1) 6 (7) 15 (9) .33 
Other Gram-positivea 1 (1) 2 (2) 5 (3) .56 
Gram-negative 35 (58) 48 (58) 81 (48) .16 
Enterobacteriaceae 32 (53) 39 (48) 65 (38) .09 
Escherichia coli 26 (43) 27 (33) 29 (17) <.001*§ 
Klebsiella pneumoniae 3 (5) 8 (10) 18 (12) .43 
Enterobacter spp  0 (0) 2 (2) 11 (6) .06 
Other Enterobactericeaeb 3 (5) 3 (4) 9 (5) .48 
FQR-Enterobacteriaceae 5 (8) 21 (26) 26 (15) 0.01# 
ESBL-producing 
Enterobacteriaceae 
2 (3) 13 (16) 30 (18) 0.02* 
Carbapenem-resistant 
Enterobacteriaceae  
0 (0) 1 (1) 8 (5) 0.10 
   Non-fermenters 3 (10) 9 (11) 16 (10) .44 
Pseudomonas aeruginosa 2 (3) 6 (7) 8 (5)  
Acinetobacter baumannii 0 (0) 0 (0) 3 (2)  
Stenotrophomonas                             
maltophilia 
0 (0) 1 (1) 3 (2)  
Other non-fermenters 1 (1) 2 (2) 2 (3)  
Other Gram-negatived 1 (2) 1 (1) 0 (0)  
Anaerobes 3 (2) 1 (1) 2 (3)  
Fungi     
Candida species 1 (2) 2 (2) 19 (11) .76 
Mixed infections 3 (5) 5 (6) 22 (13) .09 
BSI bloodstream infection, MSSA methicillin-susceptible S.aureus, MRSA methicillin-resistant S. aureus ; 
FQR, fluoroquinolone-resistant; ESBL, extended-spectrum beta-lactamase, CR carbapenem-resistant  
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Table 6 . Pathogen distribution according with source of bloodstream infection 
 PRIMARY 
BSI 
N=99 
(32%) 
UTI 
N= 35 
(11%) 
PNEUMONIA 
N=19 (6%) 
DEVICE-
RELATED  
INFECTION* 
N = 37 (12%) 
NON-
SBP  
IAI§ 
N=49 
(16%) 
SBP 
N= 50 
(16%) 
OTHER# 
N=28 
(6%) 
Gram-positive 49 (49) 6 (17) 13 (68) 26 (70) 18 (37) 17 (34) 20 (71) 
   Coagulase-negative 
staphylococci  
6 (6) 0 (0) 0(0) 13 (35) 2 (4) 2 (4) 2 (7) 
   MRSA  4 (4) 1 (3) 2 (10) 2 (5) 1 (2) 0 (0) 2 (7) 
   MSSA 13 (13) 1 (3) 5 (26) 6 (16) 3 (6) 4 (8) 10 (36) 
   Streptococcus spp 8 (8) 1 (3) 5 (26) 1 (3) 1 (2) 5 (10) 3 (11) 
   Enterococcus faecalis  6(6) 2 (6) 0 (0) 2 (3) 1 (2) 3 (6) 1 (4) 
   Enterococcus faecium  11 (11) 2 (6) 0(0) 1 (3) 6 (12) 2 (4) 1 (3) 
Gram-negative  49 (49) 29 (83) 6 (31) 12 (32) 35 (71) 31 (62) 7 (25) 
   Enterobacteriaceae  39 (39) 27 (77) 2 (10) 9 (24) 33 (67) 25 (50) 4 (14) 
      Escherichia coli  21 (21) 22 (63) 2 (10) 1 (3) 17 (35) 18 (36) 1 (4) 
      Klebsiella 
pneumoniae  
10 (10 3 (9) 0 (0) 5 (13) 7 (14) 4 (8) 1 (4) 
      Enterobacter spp 3 (3) 1 (3) 0  2(5) 4 (8) 3 (6) 1 (4) 
      FQR-  
Enterobacteriaceae 
14 (14) 13 (37) 1 (5) 14 (28) 4 (11) 6 (12) 1 (4) 
      ESBL-producing 
Enterobacteriaceae 
14 (14) 5 (14) 1 (5) 6 (16) 13 (26) 4 (8) 3 (11) 
      CR-
Enterobacteriaceae 
1 (1) 1 (3) 0 (0) 2 (5) 5 (10) 1 (2) 0 (0) 
   Non-fermenters  9 (9) 3 (9) 3 (16) 4 (11) 2 (4) 5 (10) 3 (11) 
      P. aeruginosa  5 (5) 3 (9) 2 (10) 2 (5) 2 (4) 1 (2) 1 (4) 
Fungi  
   Candida spp  
 
7 (7) 
 
0 (0) 
 
0(0) 
 
7 (19) 
 
1(2) 
 
4 (8) 
 
1 (4) 
Mixed  14 (14) 1 (3) 0 (0) 9 (24) 4 (8) 4 (8) 0 (0) 
BSI bloodstream infection, MSSA methicillin-susceptible S. aureus, MRSA methicillin-resistant S. aureus; 
FQR, fluoroquinolone-resistant; ESBL, extended-spectrum beta-lactamase, CR carbapenem-resistant; SBP 
spontaneous bacterial peritonitis  
* Device-related infection included catheter-related BSI (n=32) and TIPS related BSI (n=5) 
§Non-SBP IAI included all intrabdominal infections and biliary tract infections with exception of SBP  
# Other infection included endocarditis (n=11), skin and soft tissues (n=10) bone and joint infections (n=4) and 
surgical sites (n=4). One patients were classified having both bone and joint and surgical site infection. 
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Prevalence and risk factor for MDRO  
 
Overall, 98 (31%) BSIs were caused by MDRO. Distribution of MDRO according with 
epidemiological classification was 7% for community acquired, 22% for healthcare 
associated episodes and 70% for hospital acquired BSI (P<.001). As shown in Figures 3A 
and 3B, identification of MDRO or Candida spp was strongly associated with receipt of 
inappropriate antimicrobial or antifungal treatment in the first 24 hours.  
 
 
Figure 3 Correlation of isolated bloodstream pathogen with probability of 
inappropriate antibiotic therapy. A spearman rank coefficient and associated P value 
were calculated for most common isolated pathogens including a) Gram-negative 
bacilli and b) Gram-positive cocci plus Candida spp. The size of the bubble is relative 
to the number of isolates. 
 
In order to assess risk factors for MDRO, patients with and without MDRO bacteria were 
compared (Table 7). At multivariate analysis, adjusted for clinical severity (CLIF-SOFA) and 
length of in-hospital stay before the onset of BSI, independent factors associated to MDRO 
isolation were previous (<30 days) antimicrobial exposure [OR 2.91 (95% CI 1.73-4.88), 
P<.001] and previous (<30 days) invasive procedures [OR 2.51 (95% CI 1.48-4.24), 
P=.001], whereas SBP source of BSI was associated with a lower risk of MDRO [OR 0.30 
(95%CI 0.12-0.73), P=.008) (Table 7). 
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Table 7. Demographics, underlying disease and comorbidities associated with 
multidrug-resistant pathogens isolation among 312 cirrhotic patients with 
bloodstream infection. 
 Patients 
with 
MDRO 
  n=98  
(31%) 
Patients 
without 
MDRO BSI  
n=214 
(62%) 
P Multivariate 
analysis*, OR (95% 
CI), p 
Demographic data     
   Age (years) [mean (± SD)] 62 (±12) 61 (± 12) .87  
   Male sex 59 (60) 145 (67) .19  
Comorbidities     
   COPD 15 (15) 25 (11) .37  
   Diabetes (any stage)  39 (40) 86 (40) .92  
   Chronic kidney disease  
      Hemodilysis  
16(16) 
2 (1) 
39 (18) 
1 (1) 
.68 
.87 
 
Liver diseasea     
Hepatitis C  37 (38) 75 (35) .64  
Hepatits B 6 (6) 14 (6) 1  
Alcoholic 38 (39) 87 (41) .80  
 Hepatocellular carcinoma 15 (15) 35 (16) .81  
Baseline MELD b [median (IQR)]  15 (11-19) 14 (11-20) .46  
  Previous hospitalization 
    Previous ICU admission  
    Gastrointestinal bleeding 
    Previous hepatorenal 
syndrome  
    Previous hepatic 
encephalopathy episode  
66/96 (67) 
13/96 (13) 
23/96 (24)  
18 (18) 
27 (28) 
111/210 
(51) 
16/210 (8) 
16 (7) 
19 (9) 
42 (20) 
.009 
.10 
<.001 
.02 
.14 
 
Invasive procedures  49 (50) 55 (25) <.001 2.51 (1.48-4.24), .001 
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MDR multidrug-resistant organism, BSI bloodstream infection, CI confidence interval, SD 
standard deviation, COPD chronic obstructive pulmonary disease, MELD model for end-
stage liver disease, IQR interquartile range, ICU intensive care unit, TIPS transjugular 
intrahepatic portosystemic shunt, BL/BLI beta-lactam/beta-lactamase inhibitor, CLIF-SOFA 
chronic liver failure-sequential organ failure assessment, SBP spontaneous bacterial 
peritonitis.   
   Endoscopy 39 (40) 47 (22) .002  
   Surgery 11 (11) 15/213 (8) .19  
   TIPS 13 (13) 6 (3) <.001  
Antimicrobial exposure c 56 (57) 64 (30) <.001 2.91 (1.73-4.88), <.001 
Antibiotic prophylaxis  20 (20) 37 (17) .53  
Quinolone prophylaxis  6 (6) 6 (3) .20  
Fluoroquinolones 22 (22) 21 (10) .004  
Third generation cephalosporine 24 (24) 23 (11) .007  
BL/BLIs 25 (25) 23 (11) .001   
Time between hospital 
admission and BSI onset (days) 
[median (IQR)] 
7 (1-21) 1 (0-8) <.001  
BSI severity      
MELD at BSI [median (IQR)] 19 (14-24) 17 (12-25) .38  
CLIF-SOFA [median (IQR)] 6 (4-9) 6 (4-8) .08  
Δ- MELD 3 (0-5) 2 (0-4) .09  
BSI classification  
   Community acquired  
   Healthcare associated 
   Hospital acquired  
 
7 (7) 
22 (22) 
69 (70) 
 
53 (24)  
60 (28) 
101 (47) 
 
<.001 
.33 
<.001 
 
BSI Source     
   Primary 31 (31) 69 (32) 1  
   Catheter-related 13 (13) 20 (9) .32  
   Biliary tract 14 (14) 12 (6) .01  
   Intrabdominal  10 (8) 13 (7) .65  
   Urinary 9 (7) 26 (13) .13  
   Pneumonia 5 (4) 14 (6) .33  
   SBP 7 (7) 43 (20) .004 0.30 (0.12-0.73), .008 
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a37 patients had multiple cause of liver cirrhosis 
b baseline MELD was available in 231 patients  
c defined as exposure to one or more antibiotic drugs (≥ 3 days) in the previous 30 days   
 
 
The accuracy of the predictive model was assessed across different countries considering 
the different prevalence of MDRO in Italy, Germany, Spain and Israel which was assessed 
as 37.5%, 26.3%, 22.4% and 30.6% of BSI, respectively (Table 8).   
 
 
Table 8.  Sensitivity, specificity, area under receiver operating characteristic curve 
(aROC), positive predictive value (PPV) and negative predictive value (NPV) of the 
prediction model for MDRO (for variables included in the model see text and table 7) 
according to the prevalence of MDRO in cirrhotic patients with BSI per country. 
Country Prevalence 
(%) 
Sensitivity 
(%) 
Specificity 
(%) 
aROC PPV 
(%) 
NPV 
(%) 
Italy 37.5 19.6 92.5 0.71 61.1 65.5 
Germany 26.3 60.0 85.7 0.71 60.0 85.7 
Spain 22.4 33.3 96.2 0.70 71.4 83.3 
Israel 30.6 27.3 95.8 0.70 75.0 74.2 
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DISCUSSION 
 
The main finding of this study is that MDRO account for nearly one-third of BSI in patients 
with liver cirrhosis and are frequently associated with delays in effective treatment or 
inadequate empirical therapy, which are independent risk factors for death following a 
positive blood culture in both low and high-risk patients. Among commonly used mortality 
risk scores, we found that CLIF-SOFA and SOFA best discriminated non-surviving from 
surviving cirrhotic patients. Finally, we found that previous antimicrobial exposure, invasive 
procedures and source of infection play a role in determining the presence of MDRO. Similar 
to earlier studies, we found that alcohol abuse and HCV infection are still the main causes 
of underlying disease.(4) Most BSI episodes are acquired while in hospital or following 
frequent exposures to the healthcare environment.(9)  
 
The mortality rate of BSI was 25%, which appears significantly higher than that associated 
with BSI in general population and with other bacterial infections in patients with liver 
cirrhosis.(4, 54, 55) However we found that common sepsis criteria used to discriminate 
infection severity were less predictive of outcomes in patients with liver cirrhosis. Similar 
findings were reported in a recent analysis of  over 100,000 patients with infection and organ 
failure, where few patients with ESLD fulfill sepsis criteria consistent with their disease 
outcome.(56) Severity assessments based on parameters of organ failure  may be  more 
accurate in predicting outcome in cirrhotic patients with BSI.(50)  The CLIF-SOFA score, an 
ad hoc adjustment of SOFA criteria, was the best predictor of 30-day mortality in our study 
cohort. In addition, in our series a cut-off of 7 points of CLIF-SOFA showed a good accuracy 
in distinguishing patients with higher risk of mortality. Is worth to be noticed that altogether 
high, medium and low risk patients had a benefit, with a different degree, of adequate 
empirical treatment (figure 2c and 2d).   
  
The other major finding of this study was that besides underlying condition and infection 
severity, timely appropriate antimicrobial therapy has a major impact on the outcome of BSI, 
confirming prior results.(31, 57) The main predictor of inappropriate therapy in our patient 
cohort was isolation of a MDRO or Candida spp.  
 
The heavy prevalence of MDRO in this series is notable. We observed a substantial rate of 
MDRO in several countries, especially Italy, confirming previous single-centre studies.(9, 
11, 58) The prevalence of MDRO among BSI in cirrhotic patients was 37% in Italy, 30% in 
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Israel, 26% in Germany and 22% in Spain. It is well known that patients with liver cirrhosis 
undergo recurrent hospitalizations, invasive procedures and/or antimicrobial treatment, or 
prophylaxis, which subsequently increase the risk of acquiring a MDRO.  
   
The problem of MDROs and the related ineffectiveness of empirical treatment is a growing 
topic of importance in the management of liver cirrhosis, although most studies have focused 
solely on the role of healthcare associated infections (HAI). However, defining HAI only on 
the basis of current items, in the liver cirrhosis populations is not straightforward. For 
example, in our cohort less than 1% of patients were undergoing chronic haemodialysis. 
Similarly, the rate of residents in nursing home with liver cirrhosis reported in large surveys 
in US seems negligible.(59) As a result, common criteria for HAI were not associated with 
isolation of MDRO in our cohort, but the low sensitivity of the current definition could be 
misleading. In our study, risk factors independently associated to MDRO were antimicrobial 
exposure or undergoing invasive procedures in the previous 30 days of infection onset. By 
contrast, having a SBP as a source of infection was associated with lower risk of MDRO. 
This latter factor may seem unexpected. However, in the study of Fernandez et al,(4) among 
all infection caused by MDRO, only 9% were represented by SBP. This finding requires 
further studies for confirmation.  
 
Our study has some limitations including the heterogeneity of data due to the different 
epidemiology and different practice patterns over the different centres. This latter however 
is in line with the exploratory and observational design of the study. Another important 
limitation is that the prevalence of MDRO may be influenced by local or national ongoing 
outbreaks. To minimize the potential of bias, the study was conducted only in centres where 
an infection control programme was present.  
 
Notwithstanding these limitations, we believe that this study could give substantial, 
generalizable information on the epidemiology of BSI in liver cirrhosis and provide the basis 
for further interventional studies on the management of BSI in this setting. 
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STUDY 2. CONTINUOUS INFUSION OF BETA-LACTAM ANTIBIOTICS IN CIRRHOTIC 
PATIENTS WITH BLOODSTREAM INFECTION: RESULTS FROM A PROSPECTIVE 
MULTICENTRE OBSERVATIONAL STUDY 
 
 
METHODS 
 
The BICHROME study was a prospective, multicenter study enrolling cirrhotic patients with 
BSI. Details of methods used in the study are presented in the previous section.   
 
Population  
 
All adult (>18 years) patients with liver cirrhosis who developed BSI at the participating 
centres were included in the study. The diagnosis of liver cirrhosis was based on previous 
liver biopsy results or a composite of clinical signs and findings provided by laboratory test 
results, endoscopy and radiologic imaging. Patients with previous liver transplantation were 
excluded. Patients with subsequent episodes of BSI were excluded. Patients were followed-
up to 30 days after the BSI onset defined by the first positive blood culture. Of the patients 
initially included in the BICHROME cohort we selected patients using the following inclusion 
criteria: i) receipt adequate empirical and definitive treatment; ii) treatment with empirical (for 
at least 48h) or definite antibiotic treatment (for at least 7 days in survivors) with either 
piperacillin-tazobactam (TZP) or a carbapenem (CAR).  
We included into the continuous/extended infusion group patients who received a TZP 
loading dose of 4.5-9 g followed by 18g (or less in case of renal function impairment) per 
24h by continuous infusion, or a meropenem (MER) dose of 1-2 g followed by 2-6 g (or less 
in case of renal function impairment) per 24h of meropenem divided in 3-4 infusions of at 
least 4 hours each, or  a loading dose of 1 g imipenem and cilastatin followed by 2-3 g/  of 
imipenem-cilastatin per 24 h as a continuous infusion adjusted for renal function. 
Bloodstream infection was defined the growth of a non-common skin contaminant from ≥ 1 
blood culture (BC) or of a common skin contaminant such as diphtheroids, Bacillus species, 
Propionibacterium species, coagulase negative staphylococci (CoNS), or micrococci from ≥ 
2 BCs drawn on separate sites and reporting the same antimicrobial susceptibility test 
profile.   
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Statistical analysis 
  
Categorical variables were analyzed as absolute numbers and their relative frequencies. 
Continuous variables were analyzed as mean and standard deviation (SD) if normally 
distributed, or as median and interquartile range (IQR) if non-normally distributed. 
categorical variables were compared using the χ 2 test, whereas continuous variables were 
compared using the Mann-Whitney U or two-tailed Student’s T- test, when appropriate. 
Survival after 30 days from BSI diagnosis in patients receiving intermittent vs extended 
infusion of beta-lactams was assessed by Kaplan-Meier curves.  
Factors associated with 30-day mortality at univariate analysis were included in a Cox 
regression multivariable model to assess factors independently associated to 30-day 
mortality.     
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RESULTS 
During the study period, 323 patients with BSI were enrolled. Excluded patients had 
incomplete data (7 cases), had a single BSI caused by CoNS (2 cases) or were recipient of 
liver transplant (2 cases). Thus, 312 unique patients were analysed. Among these, 190 
patients received adequate empirical antibiotic treatment and 123 of 190 received TZP or 
CAR as empiric and/or definitive therapy. Of these 123 patients, 118 (96%) received empiric 
TZP or carbapenem and 91 (70%) of them received an intermittent administration of the 
same drug, whereas 37 patients received a continuous or extended infusion. Fifty-two 
patients received definitive therapy with TZP or CAR, 23 treated with intermittent 
administration and 27 with continuous infusion of antibiotic (figure 3). 
 
 
Figure 3. Study flow-chart. Abbreviations: TZP piperacillin-tazobactam; CAR 
carbapenems 
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Characteristics of patients included in the study  
 
Overall, the entire cohort of 123 patients were characterized as follows. Mean age was 61 
(±12) years and 83 (67%) of patients were male. The main causes of liver cirrhosis were 
viral in 43 (36%) subjects (36 cases of hepatitis C infection, 7 cases of hepatitis B infection), 
alcoholic in 32 (26%) and cryptogenic in 20 (16%) cases. In 21 cases (16%) cirrhosis was 
complicated by HCC. The median (IQR) Charlson comorbidity index were 7 (5-8). 
Comparing patients receiving intermittent administration with patients treated with 
continuous infusion of TZP or carbapenems no differences were found in demographics, 
cirrhosis characteristics and cause of hospital admission (table1). On the other hand, when 
analysing BSI characteristics, patients treated with continuous infusion of TZP or 
carbapenems were more likely to have hospital acquired infections (68% vs 43%, p=0.01), 
intra-abdominal infections (other than SBP) (34% vs 16%, p=0.03). No differences were 
found analysing severity of the infection.   
 
Table 9. Differences in demographics, underlying disease, comorbidities and 
characteristics of infection among patients receiving intermittent administration and 
patients receiving continuous infusion piperacillin-tazobactam or carbapenems 
 TOTAL, 
N=123 
(100%) 
INTERMITTENT 
INFUSION, N=85 
(69%) 
CONTINUOUS/ 
EXTENDED 
INFUSION  
N= 38 
(31%) 
P 
  Demographic data     
   Age (years) [mean (± SD)] 61 (±12) 60 (±12) 63 (± 9) 0.19 
   Male sex  83 (67) 57 (67) 26 (68) 0.82 
Liver disease a     
Viral cirrhosis 43 (36)  31 (35) 12 (32) 0.80 
Alcoholic cirrhosis 32 (26) 23 (27) 9 (24) 0.82 
NAFLD 13 (11) 8 (9) 5 (13) 0.53 
Cryptogenic 20 (16) 12 (14) 8 (21) 0.33 
   Alcoholic + viral cirrhosis  11 (9) 8 (9) 3 (8) 1  
 Hepatocellular carcinoma 21 (16) 7 (18) 14 (16) 0.79 
Admission diagnosis     
   Ascitic decompensation 17 (14) 14 (17) 3 (8) 0.26 
   Acute kidney injury 5 (4) 0 (0) 5 (4) 0.17 
   Worsening of liver disease 11 (9) 8 (10) 3 (8) 0.75 
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Hepatic encephalopathy 11 (9) 6 (7) 5 (13) 0.49 
Suspected bacterial infection  53 (44) 38 (47) 15 (39) 0.46 
Co-morbidities     
Charlson index [median (IQR)] 7 (5-8) 7 (5-9) 6 (4-8) 0.85 
Previous (<90 days) hospital 
admission  
77 (64) 55 (67) 22 (58) 0.43 
   Previous (<90 days) ICU admission  11 (9) 10 (12) 1 (3) 0.17 
BSI data     
Site of infection acquisition     
Community-acquired BSI 22 (18) 17 (20) 5 (13) 0.36 
Hospital-acquired BSI 63 (52)  37 (43) 26 (68) 0.01 
Healthcare associated   38 (30) 31 (35) 7 (18) 0.09 
Primary 39 (32) 28 (33) 11 (29) 0.66 
Pneumonia 11 (9) 9 (11) 2 (5) 0.50 
SBP 21 (16) 17 (19) 4 (10) 0.23 
Intra-abdominal (other than SBP) 27 (23) 14 (16) 13 (34) 0.03 
Urinary tract 17 (14) 13 (15) 4 (10) 0.58 
Infection severity      
   ACLF 
      Grade 1  
      Grade 2  
      Grade 3 
 
18 (15) 
18 (15) 
14 (11) 
 
15 (18) 
14 (16) 
10 (12) 
 
3 (8) 
4 (10) 
4 (10) 
0.30  
CLIF-SOFA score [median (IQR)] 7 (4-10) 6 (3-9) 7 (5-9) 0.90 
SOFA score [median (IQR)] 6 (4-9) 6 (3-8) 6 (4-9) 0.88 
MELD at BSI [median (IQR)] 19 (11-25) 17 (12-19) 19 (13-24) 0.85 
   Sepsis 95 (77) 63 (71) 32 (84) 0.28 
   Septic shock 22 (13) 18 (21) 4 (10) 0.20 
Empiric treatment  
    Piperacillin-tazobactam  
    Meropenem  
    Imipenem 
    Ertapenem 
 
81 (66) 
26 (21) 
6 (5) 
 
52 (61) 
20 (23) 
6 (7) 
 
29 (76) 
6 (16) 
0 (0) 
 
0.10 
0.33 
0.17 
Definitive treatment  
    Piperacillin-tazobactam  
    Meropenem  
    Imipenem 
    Ertapenem 
 
24 (19) 
12 (10) 
4 (3) 
3 (2) 
 
9 (10) 
7 (8) 
2 (2) 
3 (3) 
 
15 (39) 
5 (13) 
2 (2) 
0 (0) 
 
<0.001 
0.39 
0.4 
0.52 
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Microbiology  
 
Detailed pathogens distribution is showed in table 2. Patients receiving continuous infusion 
of TZP or carbapenems had higher prevalence of Gram-negative infection (82% vs 58%, 
p=0.01), including non-Escherichia coli non-Klebsiella pneumoniae Enterobacteriaceae 
(21% vs 7%, p=0.02), non-fermenting bacilli (21% vs 8%, p=0.04). We also found a trend 
toward higher incidence of carbapenem-resistant(CR)-Enterobacteriaceae (5% vs 0%) and 
extended spectrum beta-lactamase(ESBL)-producing Enterobacteriaceae (24% vs 14%) 
among patients receiving TZP or carbapenems in continuous/extended infusion with a 
significant difference in terms of any MDR-gram-negatives (32% vs 16%, p=0.05).  
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Table 10. Causative pathogen distribution among patients treated with 
piperacillin/tazobactam or carbapenem. Differences of isolates among patients 
receiving intermittent administration and among patient treated with 
continuous/extended infusion of antimicrobial. 
 TOTAL, 
N=123 
(100%) 
INTERMITTENT 
INFUSION, N=85 
(69%) 
CONTINUOUS/ 
EXTENDED INFUSION  
N= 38 (31%) 
P 
Gram-positive 42 (37) 34 (40) 8 (21) 0.04 
   Methicillin susceptible- 
Staphylococcus aureus 
22 (18) 18 (21) 4 (10) 0.20 
   Streptococcus spp 8 (6) 8 (9) 0 (0) 0.10 
   Enterococcus spp 9 (14) 10 (14) 11 (10) 0.31 
   Other gram-positivea 4 (3) 4 (5) 0(0) 0.31 
Gram-negative 80 (65) 49 (58) 31 (82) 0.01 
   Enterobacteriaceae 65 (52) 42 (49) 23 (60) 0.25 
      Escherichia coli  40 (32) 31 (36) 9 (23) 0.16 
      Klebsiella pneumoniae 11(9) 5 (6) 6 (16) 0.09 
      Other Enterobacteriaceaeb 14 (11) 6 (7) 8 (21) 0.02 
      ESBL-Enterobacteriaceae 21 (14) 12 (14) 9 (24) 0.19 
      CR-Enterobacteriaceae 2 (2) 0 (0) 2 (5) 0.09  
   Non-fermenters 15 (12) 7 (8) 8 (21) 0.04 
      Pseudomonas aeruginosa  11 (7) 5 (6) 6 (16) 0.09 
     Other non-fermenters 4 (3) 2 (2) 2 (5) 0.58 
MDR-Gram-negative 26 (21) 14 (16) 12 (32) 0.05 
Anaerobes 4 (3) 3 (3) 1 (3) 1  
a 3 cases of methicillin susceptible coagulase-negative staphylococci, 1 case of Listeria monocytogens BSI  
b 5 cases of Enterobacter spp, 3 cases of Klebsiella oxytoca, 2 cases of Citrobacter spp, 1 case of Proteus 
mirabilis, 1 case of Escherichia hermannii, 1 case of Morganella morganii    
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Outcome 
   
At the end of 30-day follow up 31 out of 123 patients (25%) died with a median (IQR) time 
to death of 9 (2-20) from index BSI. Kaplan-Meier curves indicate that patients receiving 
continuous or extended infusion of TZP or carbapenems had a significantly lower mortality 
rate (16% vs 36%, log-rank P=0.045) (figure 4a). Similar results were obtained analysing 
separately patients receiving empiric treatment with CI beta-lactams vs intermittent 
administration (P=0.019) (figure 4b) or definitive treatment (P=0.034) (figure 4c).     
 
Figure 4. Kaplan-Meier curves for 30-day mortality. Comparison of outcome in 
patients receiving continuous/extended versus intermittent infusion of piperacillin-
tazobactam or carbapenems in patients with liver cirrhosis and bloodstream 
infection. Results in the entire cohort (a) or in patients receiving empiric (b) or 
definitive (c) treatment with piperacillin-tazobactam or carbapenems.    
 
 
 
 
Similarly, the mortality rate was lower in patients treated empirically with continuous or 
extended infusion of TZP or carbapenems (11% vs 3% p=0.019). At multivariate analysis 
using a Cox regression model, after adjusting for infection severity, using CLIF-SOFA and 
source of infection, receipt of empiric continuous or extended infusion of TZP or carbapenem 
was associated with significative lower mortality [HR 0.34 (95% CI 0.11-0.93), p=0.036] 
(table 11)   
 
45 
 
Table 11. Multivariable Cox regression model for 30-day mortality  
 
 
 
 
 
 
 
Abbreviations: CLIF-SOFA chronic liver failure-sequential organ failure assessment, SBP 
spontaneous bacterial peritonitis; BSI bloodstream infection CI confidence interval  
 
 
 
 
  
Model Covariate Hazard ratio 95% CI P 
CLIF-SOFA 1.37 1.24-1.51 <0.0001 
SBP as source of BSI   2.35 1.11-4.89 0.03 
Empiric extended infusion piperacillin-
tazobactam or carbapenem   
0.32 0.11-0.93 0.04 
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DISCUSSION  
 
In this prospective multicentre study of cirrhotic patients with BSI administration of CI of TZP 
and MER was associated with improved survival. To date no studies were performed to 
assess efficacy of CI of beta-lactams in patients with liver cirrhosis. Previous studies on 
different patient population showed a significative advantage in CI over IA of beta-lactams. 
Beta-lactams show a time-dependent bactericidal effect. Therefore, they achieve the best 
bacterial killing when the time that serum concentrations remain above the minimal inhibitory 
concentration (MIC) is prolonged (t>MIC). This important pharmacokinetic parameter is 
usually achieved during continuous infusion of such drugs. 
An important aspect of our study is that the best effectiveness of treatment in terms of 
outcome was achieved when CI of beta-lactams was employed in the early phase of 
infection. In fact, empiric CI infusion of beta-lactam was an independent factor related to 
lower odds of mortality (table 11). Previous studies showed that continuous infusion of beta-
lactams when compared with bolus administration, has shown significantly higher serum 
and interstitial concentration of antibiotic in critically-ill patients during the first two days of 
treatment. (60) This aspect may be of particular interest as during the early phase of sepsis 
insufficient dose of beta-lactam antibiotics are often observed with conventional 
dosages.(61) In patients with liver cirrhosis an increased volume of distribution due to 
oedemas and ascites and lower protein binding, may be correlated with lower circulating 
drug and resulting with insufficient drug serum concentration during the first days of 
antimicrobial treatment. (34)       
Continuous infusion of beta-lactams may be also necessary dealing with difficult-to-treat 
MDR pathogens. In fact, earlier studies suggested that pathogens with higher MIC can be 
adequately treated when CI of beta-lactams is employed. This aspect is of interest in the 
field of cirrhotic patients as this setting is particularly involved by the spread of MDRs(11). 
In our study, 20% of isolates where classified as MDR Gram-negatives and the prevalence 
was higher in the group of patients receiving CI of TZP or MER.   
Beyond the major prevalence of MDR pathogens, other significative differences were found 
in patients treated with CI of TZP and MER when compared with patients receiving IA of the 
same drugs. In fact, the former group had higher prevalence of hospital acquired infections 
and IAI infections. All of these factors were previously associated with poor outcome in both 
cirrhotic and non-cirrhotic population.(23, 62-64) In addition in patients with IAI poor 
penetration of antibiotics in the abdominal district is common(63).   
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Our study has several limitations. First, the core BICHROME study was designed to explore 
the contemporary epidemiology of BSI in patients with liver cirrhosis. Thus, we did not collect 
several important variables, including serum trough levels of beta-lactams, that would 
furtherly illustrate the results of this study. Second, as the use of CI or IA was not dictated 
by study protocol an inter-centre heterogeneously may have been occurred.  
Despite these limitations, our results are consistent with previous report in non-cirrhotic 
population and come from a prospective multicentre study. This latter aspect represents the 
main strength of our report.   
In conclusion, CI of beta-lactams to treat BSI in cirrhotic patients is associated to improved 
outcome and achieve the best performance when used as empirical treatment in the early 
phase of infection.         
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STUDY 3 - DIFFERENCES IN THE ETIOLOGY AND OUTCOME OF BLOODSTREAM 
INFECTION IN PATIENTS WITH ALCOHOL-RELATED LIVER CIRRHOSIS AND NON-
ALCOHOLIC LIVER CIRRHOSIS: RESULTS FORM A PROSPECTIVE MULTICENTRE 
STUDY.   
 
METHODS  
 
The BICHROME was a prospective multicenter study conducted in Nineteen tertiary centres 
from Italy (10 centres), Spain (5 centres), Germany (2 centres), Croatia (1 centre) and Israel 
(1 centre). Details on the methods, patients’ recruitment and definitions used in the study 
are extensively described elsewhere(10).   
 
   
Population  
 
All adult (>18 years) patients with liver cirrhosis who developed BSI at the participating 
centres were included in the study. The diagnosis of liver cirrhosis and related was based 
on previous liver biopsy results or a composite of clinical signs and findings provided by 
laboratory test results, endoscopy and radiologic imaging. 
Bloodstream infection was defined the growth of a non-common skin contaminant from ≥ 1 
blood culture (BC) or of a common skin contaminant such as diphtheroids, Bacillus species, 
Propionibacterium species, coagulase negative staphylococci (CoNS), or micrococci from ≥ 
2 BCs drawn on separate sites and reporting the same antimicrobial susceptibility test 
profile.  
Patients with previous liver transplantation were excluded. Patients with subsequent 
episodes of BSI were excluded. Patients were followed-up to 30 days after the BSI onset 
defined by the first positive blood culture.  
 
 
Data collection and definitions 
 
Data was collected using an electronic case report form available at the study web site. The 
integrity of data was systematically checked, and queries were generated in case of 
inconsistent or missing data for reconciliation. The following variables were collected at the 
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moment of enrolment: demographic variables (sex, age); the cause and severity of liver 
disease according with model for end-stage liver disease (MELD) collected at baseline and 
BSI onset presence of hepatocellular carcinoma (HCC);  presence of other co-morbidities 
according with the Charlson score(44). BSI were classified as hospital acquired, healthcare 
associated, or community acquired according with Friedman criteria. Infection severity was 
assessed according with sepsis criteria, sequential organ failure assessment (SOFA), 
chronic liver failure-SOFA (CLIF-SOFA)(21, 65). We also collected cases and grade of 
acute-on-chronic liver failure (ACLF), as described by Moreau et al.(3). Outcome variables 
were collected at day 7 and 30 after BSI onset by either bed-side evaluation, outpatient visit, 
or telephone call. These included the need of intensive care unit (ICU) admission, length of 
hospital stay and 7-day and 30-day transplant-free mortality.  
 
 
Microbiology  
 
Before study onset, the use of standard diagnostic methods was required and agreed with 
all the participating centres. This included the use of an automated blood culture detector 
system, the performance of Gram stain and/or rapid test (such as MALDI-TOF, PNA FISH) 
with immediate communication of the preliminary information to the attending physicians, 
the use of an automated system (Vitek n=17, MicroScan n=2) for susceptibility testing. 
Breakpoints, screening and conformation of the main mechanisms of resistance were done 
according with EUCAST guidelines.(53) Pathogens were classified as multidrug-resistant 
according with previous criteria.(52) 
 
 
Statistical analysis  
 
Categorical variables were presented as absolute numbers and their relative frequencies 
and were compared using the chi-square test or Fisher exact test when appropriate.  
Quantitative variables were presented as mean and standard deviation (SD) if normally 
distributed or as median and interquartile range (IQR) if non-normally distributed. Non-
normally distributed continuous variables were compared using the Mann-Whitney U test, 
normally distributed continuous variables were compared using the t test. The analysis of 
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variance (ANOVA) followed by the Bonferroni post-hoc test, or the Kruskal-Wallis followed 
by the Dunnett post-hoc test was performed when three or more groups were compared. 
To assess risk factors for isolation of GPC, variables associated (p<0.1) to GPC at univariate 
analysis were entered in multivariate logistic regression model. The calibration of the model 
was assessed by Hosmer-Lemeshow goodness-of-fit test and discrimination was assessed 
by the analysis of area under the receiver-operator curve (ROC). All variables were explored 
for interaction or collinearity. Difference in outcome in patients with and without alcohol 
related cirrhosis were compared using Kaplan-Meier survival curves.  
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RESULTS 
 
During the study period 323 patients with BSI were evaluated for inclusion in the study. 
Study flow chart is shown in Figure 1: 11 patients met at least one exclusion criterium and 
25 patients were excluded because presented multiple cause of liver disease (24 patients 
with both viral and alcoholic cirrhosis and 1 patient with both autoimmune and alcoholic 
cirrhosis). Thus, 287 patients were analysed in this study. Overall, 185 (64%) were male 
and mean (±SD) age was 61(±12) years. Distribution of causes of liver cirrhosis were as 
follows: 109 (38%) patients had viral cirrhosis (89 cases of HCV infection, 17 cases of HBV 
infection, 3 cases of mixed HBV-HCV infection), 99 (34%) patients had alcoholic liver 
disease (ALD) and 79 (28%) patients had non-viral non-alcoholic cirrhosis including 44 
cryptogenic cirrhosis, 24 cases of cirrhosis due to non-alcoholic fatty liver disease (NAFLD), 
6 autoimmune hepatitis, 5 primary biliary cirrhosis (figure 1). 
 
 
Figure 5 Study Flow-chart 
 
Bloodstream infection in alcoholic cirrhosis compared with other causes of liver disease.           
Comparison of BSI in patients with ALD, viral cirrhosis and non-alcoholic non-viral cirrhosis 
is shown in table 12.  Briefly, patients with ALD were younger (mean age 57±10, p<0.001) 
and mostly male (p=0.02) and presented a lower number of comorbidities when compared 
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with both patients with viral cirrhosis or non-viral non-alcoholic cirrhosis. At BSI diagnosis, 
patients with ALD appeared more severe than those reported in other groups, as showed 
by higher SOFA (p=0.03) or CLIF-SOFA (p=0.03) and higher frequency of septic shock 
(22%, p=0.002).  
 
Table 12 Difference in demographic characteristics and source and severity of 
bloodstream infection in 287 patients with liver cirrhosis according with cause of liver 
disease 
 TOTAL, 
N=287 
(100%) 
PATIENTS 
WITH 
ALCOHOLIC 
CIRRHOSIS 
=99  
(34%) 
PATIENTS 
WITH VIRAL 
CIRRHOSIS   
N=109  
(38%) 
PATIENTS 
WITH 
OTHER 
CIRRHOSIS 
AETIOLOGY 
N=105 (34%) 
P 
Demographic data      
   Age (years) [mean (± SD)] 61 (±12) 57 (±10) 64 (± 13) 63 (± 12) 0.26 
   Male sex  185 (64) 76 (77) 66 (61) 43 (54) 0.02*§ 
Co-morbidities       
Charlson index [median 
(IQR)] 
7 (5-9) 5 (3-6) 7 (4-9) 7 (5-9) <0.001*§ 
 Hepatocellular carcinoma 47 (16) 12 (12) 25 (23) 10 (13) 0.06* 
Baseline MELD [median 
(IQR))  
15 (10-19) 16 (11-21) 15 (13-17) 14 (9-19) 0.42 
Admission diagnosis       
   Ascitic decompensation 40/281 (14) 20 (20) 11 (10) 9 (12) 0.10 
   GI-bleeding 15/281 (5) 7 (7) 4 (4) 4 (5) 0.57 
Hepatic encephalopathy 28/281 (10) 10 (10) 14 (13) 4 (5) 0.28 
Suspected bacterial 
infection  
122/281 
(42) 
32 (32) 50 (47) 40 (53) 0.015*§ 
BSI data      
Site of infection acquisition      
Community-acquired BSI 53 (19) 23 (23) 17 (16) 13 (16) 0.31 
Hospital-acquired BSI 161 (54)  58 (59) 57 (52) 46 (58) 0.59 
Healthcare associated   73 (25) 18 (18) 35 (32) 20 (25) 0.07 
Primary 94 (33) 37 (38) 28 (26) 29 (37) 0.14 
SBP 50 (16) 15 (15) 16 (15) 19 (18) 0.79 
Intra-abdominal (other than 
SBP) 
48 (17) 9 (9) 22 (20) 17 (21) 0.04*§ 
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Urinary tract 32 (11) 7 (7) 16 (15) 9 (11) 0.22 
Pneumonia 18 (6) 10 (10) 6 (5) 2 (2) 0.10 
Infection severity       
   ACLF 
      Grade 1 ACLF 
      Grade 2 ACLF 
      Grade 3 ACLF     
105 (37) 
44 (15) 
36 (12) 
26 (9) 
45 (45) 
14 (14) 
16 (16) 
16 (16) 
36 (32) 
18 (16) 
13 (12) 
5 (5) 
25 (32) 
12 (15) 
7 (9) 
5 (6) 
0.09 
0.04 
SOFA score [median (IQR)] 6 (3-9) 6 (4-8) 6 (4-7) 5 (4-7) 0.03*§ 
MELD at BSI [median (IQR)] 18 (12-24) 18 (12-26) 19 (14-24) 17 (12-23) 0.35 
   Septic shock 38 (13) 22 (22) 6 (5) 10 (13) 0.002* 
Outcome       
   ICU admission 77 (27) 38 (38) 18 (17) 21 (27) 0.002* 
   Need for mechanical 
ventilation 
46 (16) 21 (21) 10 (9) 15 (20) 0.05 
   In-hospital mortality  87 (31) 32 (33) 31 (29) 24 (31) 0.89 
   7-day mortality  33 (11) 17 (17) 8 (7)  6 (8) 0.04 
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Microbiology  
Significant differences in BSI causative pathogens were found comparing patients with 
different cirrhosis etiologies (Table 13). Indeed, GPC-BSI (0.002), including Streptococcus 
spp BSI (p=0.03) were found more frequently in patients with alcohol related cirrhosis. In 
contrast, GNB were detected less frequently in this group of patients if compared with those 
with viral cirrhosis and non-viral non-alcoholic cirrhosis (p<0.001) with significant differences 
in the prevalence of Enterobacteriaceae (p=0.004), including Escherichia coli (p=0.02), and 
different frequency of non-fermenting bacilli, such as Pseudomonas aeruginosa (p=0.05), 
among the groups. Conversely, we did not find differences in the prevalence of MDR 
pathogens.   
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Table 13. Causative pathogen distribution of 287 BSI in cirrhotic patients and 
differences between patients with alcoholic liver disease (ALD), viral cirrhosis and 
other causes of liver disease. 
 TOTAL, N=287 
EPISODES 
(100%) 
ALCOHOLIC 
CIRRHOSIS 
N=99 BSI 
EPISODES 
(32%) 
VIRAL 
CIRRHOSIS 
N=109 BSI 
EPISODES 
(35%) 
PATIENTS 
WITH OTHER 
CONDITIONS 
N=76 (34%) 
P 
Gram positive 133 (46) 58 (59) 38 (35) 37 (47) 0.003*§ 
Coagulase negative 
staphylococci 
23 (8) 12 (12) 8 (7) 3 (4) 0.12 
Staphylococcus aureus 47 (17) 21 (21) 12 (11) 14 (17) 0.13 
Staphylococcus aureus 
(MSSA) 
38 (13) 17 (17) 9 (8) 12 (15) 0.13 
Staphylococcus aureus 
(MRSA) 
9 (3) 4 (4) 3 (3) 2 (2) 0.81 
Streptococcus spp 21 (7) 13 (13) 5 (5) 3 (4) 0.02*§ 
Enterococcus spp 39 (14) 14 (14) 11 (10) 14 (18) 0.31 
Gram negative 152 (53) 36 (36) 70 (64) 46 (58) <0.001*§ 
Enterobacteriaceae 127 (44) 31 (32) 59 (54) 37 (47) 0.004* 
   Escherichia coli  76 (26) 17 (17) 37 (34) 22 (28) 0.02* 
   Klebsiella 
pneumoniae 
29 (10) 7 (7) 13 (12) 9 (11) 0.46 
   ESBL-
Enterobacteriaceae 
42 (15) 10 (10) 21 (19) 11 (14) 0.17 
   CR-
Enterobacteriaceae 
9 (3) 1 (1) 4 (4) 4 (5) 0.28  
Non-fermenters 25 (9) 4 (4) 11 (10) 10 (13) 0.10 
Pseudomonas 
aeruginosa  
15 (5) 1 (1) 7 (6) 7 (9) 0.05* 
 
Fungi      
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Candida species 22 (7) 8 (8) 7 (6) 7 (7) 0.87 
Mixed infections 28 (10) 9 (9) 6 (5) 13 (16) 0.04 
MDR pathogen 98 (31) 28 (29) 35 (32) 35 (33) 0.75 
 
 
Outcome of patients with alcoholic cirrhosis compared with other conditions 
During the study period, 77 (26%) patients needed ICU admission and 46 (16%) were 
mechanically ventilated.  
Patients with ALD were admitted in ICU (p=0.002), underwent to mechanical ventilation 
(P=0.05) more frequently when compared with both patients with viral cirrhosis or non-viral 
non-alcoholic cirrhosis.    
Overall, 87/287 (30%) patients died during the in-hospital stay. Thirty-day mortality rate did 
not differ among the groups (p=0.91) Conversely, Kaplan-Meier survival curves showed 
worse 7-day survival of patients with ALD if compared with patients with cirrhosis due to 
other causes (p=0.04) (figure 6a and 6b).   
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Figure 6. Differences in 7-day (a) and 30-day (b) mortality in patients with alcoholic 
liver disease, viral cirrhosis and other conditions. 
 
 
 
 
 
Risk factors for BSI caused by Gram-positive cocci 
 
After excluding 21 patients with mixed infections with isolation of both GPC and GNB and 
patients with fungal BSI, 112 patients with monomicrobial BSI caused by GPC were 
compared with 140 patients with monomicrobial BSI caused by Gram-negative bacilli (GNB) 
(table 14). 
58 
 
Table 14. Differences in demographics, underlying disease, source and severity of 
infection in patients with monomicrobial bloodstream infection caused by Gram-
positive cocci and monomicrobial bloodstream infection caused by Gram-negatives 
 PATIENTS WITH ISOLATION 
OF GRAM-POSITIVE COCCI 
N=112 
(45%) 
PATIENTS WITHOUT 
ISOLATION OF GRAM-
POSITIVE COCCI N= 140 
(55%) 
P 
Demographic data    
   Age (years) [mean (± 
SD)] 
61 (±10) 62 (± 14) 0.16 
   Male sex  77 (68) 85 (61) 0.18 
Liver disease    
Viral cirrhosis  33 (29) 66 (47) 0.004 
Alcoholic 53 (47) 34 (24) <0.001 
Cryptogenic  18 (13) 26 (17) 0.43 
Non-alcoholic fatty liver 
disease 
15 (11) 9 (6) 0.13 
Autoimmune 4 (3) 2 (2) 0.51 
 Hepatocellular carcinoma 15 (13) 28 (20) 0.16 
Baseline MELD [Median 
(IQR)] 
15 (10-19) 14 (9-29) 0.56 
Comorbidities     
   Chronic renal failure  27 (24) 20 (14) 0.05 
   Diabetes 
        Diabetes with organ 
damage 
54 (48) 
28 (25) 
50 (37) 
17 (12) 
0.04 
0.008 
   Charlson score  6 (4-8) 7 (5-9) 0.56 
Previous (<90 days) 
hospital admission  
60 (54) 81 (59) 0.42 
   Previous (<90 days) ICU 
admission  
14 (13) 7 (5) 0.03 
Admission diagnosis     
   Ascitic decompensation 19 (17) 15 (11) 0.50 
   Acute kidney injury  4 (4) 3 (2) 0.81 
   Worsening of liver 
function  
11 (10) 9 (7) 0.33 
Hepatic encephalopathy 5 (5) 19 (14) 0.02 
Scheduled procedure 5 (3) 14 (9) 0.06 
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Complications before 
BSI (<30gg) 
   
   Invasive procedure 51 (33) 48 (37) 0.53 
   Hepatorenal syndrome 20 (15) 12 (8) 0.05 
   SBP episode 11 (8) 7 (4) 0.19 
  GI bleeding 22 (16) 14 (9) 0.048 
  Surgery 12 (9) 11 (7) 0.61 
Antibiotic exposure 
(previous 30 days) 
37 (33) 55 (39) 0.30 
   Antibiotic prophylaxis 17 (15) 29 (21) 0.32 
   Quinolone prophylaxis 3 (3) 6 (4) 0.49 
BSI data    
Site of infection acquisition    
Community-acquired BSI 20 (18) 31 (22) 0.40 
Hospital-acquired BSI 64 (57) 68 (49) 0.17 
Healthcare associated   28 (25) 41 (29) 0.44 
Source    
Primary 37 (33) 43 (31) 0.69 
SBP 12 (11) 27 (20) 0.06 
Urinary tract 5 (4) 26 (19) 0.001 
Pneumonia 13 (12) 5 (4) 0.01 
   SSTI 6 (5) 1 (1) 0.03 
   Intra-abdominal (other 
than SBP) 
13 (12) 31 (22) 0.02 
   Device-related infection 17 (15) 7 (5) 0.006 
Infection severity     
   ACLF 
      ACLF grade 
      Grade 1  
      Grade 2  
      Grade 3 
45 (40) 
 
21 (19) 
13 (12) 
11 (10) 
47 (33) 
 
19 (14) 
19 (14) 
11 (8) 
0.28 
0.61 
   SOFA score [median 
(IQR)] 
5 (3-8) 6 (4-8) 0.30 
   Septic shock 19 (17) 14 (10) 0.10 
 
Compared with patients with GNB, patients with GPC isolated in the BC had more frequently 
ALD [53 (47%) vs. 34 (24%), p<0.001], chronic renal failure [27 (24%) vs. 20 (14%), p=0.05], 
diabetes with organ damage [28 (25%) vs. 17 (12%), p=0.008], were admitted at ICU more 
frequently in the 90 days before the index BSI [14 (13) vs. 7 (5), p=0.03] and had a previous 
(<30 days) episode of hepatorenal syndrome [20 (15) vs 12 (8), P=0.05] or gastrointestinal 
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bleeding [22 (16%) vs. 14 (9), P=0.048] more frequently. Moreover, source of infection 
differed significantly among the patients with and without BSI caused by GPC. Indeed, 
individuals with GPC were had more frequently pneumonia [13 (12%) vs. 5 (4%), P=0.01] 
skin and soft tissue infection (SSTI) [6 (5%) vs 1(1%) and device related infection [17 (15%) 
vs 7 (5%), P=0.006] than patients with GNB. At multivariate analysis factors independently 
associated to isolation of GPC were alcoholic cirrhosis [OR 2.02 (95% CI 1,18-3.48), 
p=0.03], device-related infection [OR 3.08 (95 % CI 1.35-6.69), p=0.007], pneumonia as 
source of BSI [OR 3.81 (95% CI 1.23-11.79), p=0.02], previous hepatorenal syndrome [OR 
2.54 (95% CI 1.11-5.85), p=0.03] and diabetes with organ damage [OR 2.52 (95% CI 1.27-
4.99), P=0.008] (table 15)  
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Table 15. Logistic regression model assessing independent risk factors for isolation 
of Gram-positive in cirrhotic patients with bloodstream infection. 
 
  
Model Covariate Odds ratio 95% CI P 
Pneumonia 3.81 1.23-11.79 0.02 
Device-related infection  3.08 1.35-6.69 0.007 
Alcohol-related cirrhosis  2.02 1.18-3.48 0.01 
Previous hepatorenal syndrome   2.54 1.11-5.85 0.03 
Diabetes with organ damage 2.52 1.27-4.99 0.008 
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DISCUSSION 
The main results of this study are that patients with alcoholic cirrhosis developing an episode 
of BSI are significantly younger and present a lower number of comorbidities when 
compared with the other groups. Conversely, they presented more severe infection with a 
significant higher unadjusted 7-day mortality. In addition, GPC are the main cause of BSI in 
this setting. 
Previous studies demonstrated that alcohol abuser may acquire a dysregulation of immune 
system that include both impairment of its function and hyperexpression of inflammatory 
markers. Additionally, a higher incidence of ACLF in cirrhotic patients admitted for an 
episode of acute decompensation was observed in alcohol abuser in a large multicenter 
study (the CANONIC study)(3). An additional sub-analysis of the CANONIC study found a 
higher level of pro-inflammatory mediators in patients with ACLF caused by alcohol abuse 
when compared with patients with ACLF precipitated by other factors.(66). These studies 
may partially explain the higher severity of infection shown by patients with alcoholic 
cirrhosis in our study.  
Alcohol abuse was previously found as a predictor of mortality in patients with pneumonia 
or invasive pneumococcal disease in studies performed in general population(67, 68). 
However, there is a lack of studies evaluating the impact of different causes of cirrhosis on 
infection-related mortality. In a previous retrospective study including episodes of bacterial 
infection among patients with liver cirrhosis, a non-statistically significant trend toward a 
higher in-hospital mortality was observed among patients with alcoholic liver disease 
compared with patients with non-alcoholic liver disease (21% versus 15%, P=0.102)(22). A 
similar non-statistical trend toward a higher incidence of pneumonia in patients with ALD 
was observed also our study and pneumonia, in turn was previously associated to higher 
mortality when compared with other source of infection in patients with liver cirrhosis and in 
general hospital population(69, 70).   This finding may further explain the worse outcome of 
BSI observed in patients with ALD.  
Another interesting finding of this study is the different distribution of pathogens according 
with the underlying cause of ESLD. In fact, the prevalence of GPC BSI in patients with 
alcoholic cirrhosis versus viral cirrhosis was significantly higher, [ALD (59%) vs others (40%) 
vs 40%, p=0.003)]. In addition, alcoholic cirrhosis was found as an independent risk factor 
for infection caused by GPC in our cohort. Indeed, alcohol abuse is a well-known risk factor 
for pneumonia, invasive pneumococcal disease and skin and soft tissue infection were GPC 
are important causative pathogens (71-75).  Some previous single-centre studies reported 
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a growing incidence of infections caused by GPC in patients with alcoholic liver disease. In 
a study including 117 cases of BSI in cirrhotic patients a trend toward a higher incidence of 
GPC among patients with alcoholic cirrhosis was observed(76). In another report, Campillo 
et al found a prevalence of 70% of infections caused by GPC in a series of 200 cirrhotic 
patients, 175 of whom had alcohol-associated cirrhosis. Similarly, in a study enrolling all 
cases of positive-culture SBP in three different Danish hospitals, GPC were the main 
causative pathogens. In such series patients with underlying alcohol-related cirrhosis was 
76%.(77) Finally, our findings are consistent with the study of Sargenti et al which found 
higher prevalence of GPC and pneumonia among patients with alcoholic liver disease when 
compared with patients with non-alcoholic cirrhosis. (58) If this finding will be further 
confirmed, the pathogenesis of infection in patients with liver cirrhosis may need to be 
revisited with respect to the underlying cause of the liver disease. In fact, in add 
Unlike previous studies we did not find any association between quinolone prophylaxis and 
prevalence of BSI caused by GPC(78). However, the rate of patients receiving quinolone 
prophylaxis was very low in our series (10 patients, 3%).  
According with our results some important indication may be drawn. In cirrhotic patients with 
pneumonia, device-related infection, the empirical antibiotic treatment should comprise anti-
Gram-positive spectrum. In addition, in cirrhotic patients with ALD and non-urinary tract 
infection an empirical anti-Gram-positive coverage should be considered. Furtherly, the 
choice of anti-Gram-positive drug should be based on site of infection and local prevalence 
of penicillin-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus 
aureus and vancomycin-resistant enterococci.    
Our study has some limitations including the heterogeneity of data due to the different 
epidemiology and different practice patterns over the different centers. Also, the number of 
patients with alcoholic cirrhosis was different among center sited in Italy and other countries 
such as Germany and this may have had an impact in determining the different distribution 
of pathogens among patients with different underlying cause of cirrhosis. However, after 
entering the country of enrollment into the multivariable model we did not find any 
differences in either model results or model calibration and discrimination.  
Another important limitation is that the core BICHROME study did not aim specifically to find 
differences in BSI etiology in patients with alcoholic cirrhosis. Thus, we did not collect some 
important variables such as recent active alcohol consumption or diagnosis of severe 
alcoholic hepatitis treated with steroids, which could had help us to better characterize our 
cohort(79). Notwithstanding these limitations we believe that this study provides some 
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important and novel information about the epidemiology and outcome of BSI in patients with 
alcoholic cirrhosis.  
In conclusion, alcoholic liver disease is common in cirrhotic patients who develop an episode 
of BSI. Among patients, with ALD a different causative pathogen distribution is found with 
higher prevalence of gram-positive cocci if compared with patients with viral cirrhosis or 
other cause of cirrhosis. In addition, despite they present a lower number of comorbidities 
and are younger, BSI in patients with ALD is more severe. Therefore, this group of patients 
need ICU admission and mechanical ventilation more frequently and present a lower 7-day 
survival rate if compared with patients with other underlying liver disease.  
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STUDY 4. EPIDEMIOLOGY OF ACUTE-ON-CHRONIC LIVER FAILURE ASSOCIATED 
WITH BACTERIAL INFECTION IN PATIENTS WITH LIVER CIRRHOSIS: RISK FACTORS 
AND OUTCOME 
 
METHODS 
 
Study design  
We conducted a prospective observational study from January 2014 to March 2016 at the 
S. Orsola-Malpighi University Hospital, Bologna and at the “Infermi” Hospital of Rimini, a 
tertiary teaching-hospital and a community hospital, respectively. The study was approved 
by the local institutional review boards. Written informed consent was obtained from patients 
or from legal surrogates before enrolment according to the 1975 Declaration of Helsinki. 
 
Population  
Consecutive patients with liver cirrhosis and acute decompensation (AD) admitted to the 
hospital were included in the study. The diagnosis of LC was based on previous liver biopsy 
findings or a composite of clinical signs and findings provided by laboratory test, endoscopy, 
and radiologic imaging. Exclusion criteria were: i) admission for a scheduled procedure; ii) 
hepatocellular carcinoma (HCC) beyond the Milan criteria [1]; iii) metastatic extrahepatic 
malignancy; iv) previous liver transplantation.    
 
Patients recruitment and management  
In any participating center, a sub-investigator was in charge to screen al potential cirrhotic 
patients with acute decompensation through careful evaluation of any newly admitted or 
transferred patient. All patients were enrolled at admission and daily evaluated during the 
entire in-hospital stay for potential development of ACLF and/or bacterial infection. All 
patients were managed according with international and local guidelines. Medical 
treatments and management of AD or ALCF, empirical and definitive antibiotic treatment 
was not dictated by study protocol.   
 
Data collection    
Data were collected using an online electronic case report form shared in the study website. 
The integrity of data was systematically checked by an investigator before being entered 
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into the database and by monthly assessment of data completeness and consistency. In 
case of inconsistent or missing data, queries were generated and distributed to the 
participating site investigators for reconciliation. Every case of infection was managed and 
reviewed by an infectious disease specialist and by a hepatologist. The following data were 
collected at the time of enrolment: demographic characteristics; etiology of cirrhosis, 
laboratory data and clinical data including the presence of hepatocellular carcinoma (HCC) 
and presence of other co-morbidities according with Charlson score (44).  Basing on the 
collected data the Model for End-stage Liver Disease (MELD), Child-Turcotte-Pugh, CLIF-
OF, CLIF-AD and CLIF-ACLF scores were calculated for each patient when appropriate (30, 
80). 
During hospitalization additional information were collected in case of invasive diagnostic or 
therapeutic procedures including esophagogastroduodenoscopy, colonoscopy, endoscopic 
retrograde cholangiopancreatography, endoscopic ultrasound, TIPS insertion, biliary 
procedures including biliary percutaneous drainage and/or stenting, HCC treatments.  
For patients admitted due to a bacterial infection or who developed a bacterial infection 
during the hospital stay the following data were also collected:  epidemiological classification 
of infection; severity of infection assessed with SOFA, CLIF-SOFA. Similarly, infection site, 
microbiology culture and their susceptibility data, and antibiotics administered as empirical 
or definitive therapy based on susceptibility reports were recorded. For patients with multiple 
admissions during the study period only the first admission was included in the analysis.  
Patients were actively followed up for transplant status and survival during hospitalization 
and, after discharge, up to 1-year.   
 
Definitions 
Acute decompensation was defined by i) acute onset of grade 2 or grade 3 ascites, 
according to the International Ascites Club Classification (81); ii) new episode of hepatic 
encephalopathy in  patient with previous normal consciousness and no evidence of an acute 
neurologic disease; iii) upper or lower gastrointestinal bleeding; iv) bacterial infection. The 
CLIF-SOFA score was calculated as described by Moreau et al. and ACLF was diagnosed 
and classified accordingly (30). Organ failures were assessed according the following 
criteria: liver failure was defined by a serum bilirubin level of ≥12.0 mg/dL; kidney failure was 
defined by a serum creatinine level of ≥ 2.0 mg/dL or the use of renal replacement therapy; 
cerebral failure was defined by grade III or IV hepatic encephalopathy, according to the West 
Haven classification; coagulation failure was defined by an international normalized ratio 2.5 
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and/or a platelet count of <20 X109/L; circulatory failure was defined by the use of dopamine, 
dobutamine, or terlipressin.. Any case of ACLF diagnosed simultaneously to bacterial or 
fungal infection or occurring within 28 days from the diagnosis of bacterial or fungal infection 
in patients without documentation of any other common precipitating event of ACLF, were 
defined as infection-related ACLF. Any case of bacterial infection diagnosed after ACLF was 
not included in this group.    
Severity of infection was assessed with sepsis 3 criteria, sequential organ failure 
assessment (SOFA), quick-SOFA (qSOFA) and CLIF-SOFA. Pneumonia was defined as 
the radiologic evidence of a new, or progression of a previous, pulmonary infiltrate plus at 
least two of the following criteria: fever >38ºC, cough, purulent sputum, dyspnea or >20 bpm, 
pleuritic chest pain, and a leucocyte count of >10,000/mm3 or <4,000/mm3; urinary tract 
infection (UTI) was diagnosed in the presence of either one of the following criteria: i)flank 
pain, which must have onset or worsened within 7 day, ii) costovertebral angle tenderness 
on examination, iii) dysuria, urgency, frequency, and/or suprapubic pain plus at least one of 
the following:  i) fever > 38°C; ii) nausea and vomiting. Uncomplicated lower urinary tract 
infections were excluded. Spontaneous bacterial peritonitis (SBP) was defined, in presence 
of ≥ 250 polymorphonuclear cells/ml in ascitic fluid examination. Intrabdominal infection (IAI) 
(other than PBS) was defined by new onset of fever and/or abdominal pain plus new or 
worsening radiological images of abscess, bowel perforation, appendicitis, diverticulitis and 
post-surgical effusion with or without peritonitis(82). Cholangitis or biliary tract infections 
were diagnosed as defined elsewhere(83). Skin and soft tissue infection (SSTI) was 
diagnosed in presence of purulent infections (cutaneous abscesses, furuncles, carbuncles) 
or in case of non-purulent infections (cellulitis, erysipelas or necrotizing infections). 
Bloodstream infection (BSI) were defined as true, clinically significant episode of 
bloodstream infection diagnosed during the study period. Episodes in which a potential 
contaminant (e.g., coagulase‐negative staphylococci) was isolated only in one set of blood 
cultures without clinical evidence of infection were excluded. All BSI that were not secondary 
to an infection at another body site were defined primary BSI. Bacteremic infections included 
both primary BSI and any infection to another body site with positive blood cultures.   
Patients were classified as having: i) hospital acquired infection if infection signs/symptoms 
started >48 hours after hospital admission, or in less than 48 hours after hospital discharge; 
healthcare associated infections according with standard criteria; community acquired 
infections in all other cases (51). Empiric antibiotic therapy was defined as the antibiotic 
administration before susceptibility report was available. For culture-positive infection 
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empiric antibiotic therapy was considered as appropriate when at least one in vitro active 
antibiotic (according with the susceptibility pattern of the isolate) was administered within 24 
hours after drawing samples. In case of culture-negative infection appropriate empiric 
therapy was defined in base of infection site according with a recent international consensus 
paper on cirrhotic patients(41).  Delayed or no antibiotic administration within this time frame 
is considered as inappropriate empiric therapy.  
 
Statistical analysis  
Categorical data were presented as absolute number and frequency while continuous data 
were reported as mean and standard deviation (SD), if normally distributed, or as median 
and interquartile range (IQR) if non-normally distributed.  The Kolmogorov-Smirnov test and 
the Levene test were used to assess the normality of distribution and homogeneity of 
variances, afterward the unpaired student t-test or the Mann-Whitney U test were used to 
compare differences between groups when appropriate.  The analysis of variance (ANOVA) 
followed by the Bonferroni post-oc test, or the Kruskal-Wallis followed by the Dunnett post-
oc test was performed when three or more groups were compared.  
To identify the risk factors for ACLF in patents with bacterial infection patients with bacterial 
infection developing ACLF (infection-related ACLF) were compared with patients with 
uncomplicated bacterial infection.  Following univariate analysis, factors associated with 
ACLF (p<0.10) at were included in a multivariate logistic regression model. The calibration 
of the model was assessed by Hosmer-Lemeshow goodness-of-fit test and discrimination 
was assessed by the analysis of area under the receiver-operator curve (ROC). All variables 
were explored for interaction or collinearity. 
To explore the relationship between bacterial infections and 1-year mortality rates survival 
curves were plotted according the Kaplan Meier method. Differences in survival rates were 
evaluated by means of Log-Rank test. Because long term survival may be influenced by a 
great number of underlying conditions, factors associated to 1-year mortality identified in 
univariate analysis (P<0.10) were used to develop a Cox regression model. Because several 
prognostic scores (i.e. MELD, MELD-Na, CLIFc-AD score) displayed collinearity, the 
performance of every single score was evaluated by area under the receiver operating 
characteristics (AUROC) curve. Therefore, we introduced only the best performing score(s) 
as continuous variable in the final Cox regression model. The impact of bacterial infection 
and ACLF was evaluated by entering these variables manually into the baseline Cox 
regression mortality risk model to estimate their effect on mortality.  Al test were two-sided 
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and values of p <0.05 were considered statistically significant. The analysis was performed 
by the Statistical Package for Social Sciences (SPSS v.21) software (IBM corp.) 
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RESULTS 
 
Study population 
During the study period 1140 consecutive hospital admissions to regular wards involving 
916 cirrhotic patients were recorded. Of the 916 patients, 399 were electively admitted for 
scheduled diagnostic or invasive procedure and were excluded from the current analysis. 
Thus, the study cohort comprises 516 patients consecutively admitted for an episode of AD 
 of the disease (Figure 1).  
 
Figure 7. Details on patient’s disposition. During the study period 916 cirrhotic patients were enrolled. Four 
hundred patients were admitted for scheduled diagnostic or therapeutic procedures and were excluded from the 
analysis. Therefore, the study population comprises 516 consecutive patients admitted for acute decompensation 
(AD) of the disease. A bacterial infection was diagnosed at admission or during the hospitalization in 169 patients, 
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among those, 76 developed Acute-on-Chronic Liver Failure (ACLF). Among patients without bacterial infection 
ACLF occurred in 89 subjects. 
Comparison of patients with and without infections 
 
One hundred sixty-nine (33%) patients presented at least an episode of bacterial or fungal 
infection. Of these, 108 (21%) cases were diagnosed at the time of admission whereas other 
61 (12%) were classified as hospital-acquired infections. In the remaining 347 (67%) 
subjects, bacterial infection was not present neither at admission nor during hospitalization 
(Figure 7).  
Demographic and clinical data at admission of patients presenting or not an infection at 
admission or during hospitalization were reported in Table 16. The groups did not differ in 
terms of age, sex, etiology of cirrhosis, and clinical complications. Higher CRP levels were 
observed in all infected, whereas WBC count was higher at admission inly in patients with 
CA or HCA infections. In terms of prognostic scores, MELD-Na was higher in all infected 
patients at admission. On the other hand MELD was higher only in patients developing HA 
infections. Similarly, the latter group presented more frequently ACLF at hospital admission. 
Interestingly, treatment with rifaximin was significantly more frequent in patients without 
bacterial infection, while no differences were seen regarding the assumption of proton pump 
inhibitors, beta-blockers, and quinolones. Finally, co-morbidities and Charlson score were 
similar between the three groups. During the in-hospital stay both patients with CA/HCA and 
patients with HA infection developed ACLF more frequently than non-infected patients  
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Table 16. Clinical characteristics of the 516 patients with liver cirrhosis admitted for 
acute decompensation. Patients were divided according to the presence or not of a 
bacterial infection at the time of admission or the development of a nosocomial 
bacterial infection. Data are presented as frequencies [n(%)] or mean (±SD)/median 
(IQR) according to their distribution. 
  NO 
BACTERIAL 
INFECTION  
BACTERIAL 
INFECTION  
AT ADMISSION 
BACTERIAL 
INFECTION 
DURING 
HOSPITALIZATION  
P 
 n 347 108 61  
Anthropometric data     
 Age (years) 61 (51-72) 64 (53-74) 61 (52-72) 0.470 
 Male sex 209 (60) 68 (62) 43 (73) 0.180 
Etiology of cirrhosis1     
 Viral 142 (41) 51 (47) 24 (39) 0.461 
 Alcohol 71 (21) 22 (20) 18 (29) 0.270 
 NASH 19 (6) 8 (7) 5 (8) 0.606 
 Viral and alcohol 45 (13) 7 (6) 3 (5) 0.049 
 Viral and NASH 11 (3) 1 (1) 1 (2) 0.385 
 Alcohol and NASH 6 (2) 1 (1) 3 (5) 0.173 
 Other 58 (17) 19 (18) 10 (16) 0.972 
AD at admission     
 Ascites 143 (41) 45 (42) 34 (56) 0.102 
 HE 107 (31) 22 (20) 11 (18) 0.024 
 Liver failure 47 (13) 9 (8) 12 (20) 0.105 
 Renal failure 25 (7) 4 (4) 8 (13) 0.075 
 GI bleeding 28 (8) 2 (2) 6 (10) 0.056 
Biochemical and hemodynamic data    
 WBC (109/L) 5.2 (3.5-7.4) 7.8 (5.0-10.9) § 5.6 (3.6-9.2) <0.00
1 
 CRP (mg/dL) 0.91 (0.33-1.70) 3.94 (1.66-8.30) § 2.62 (0.58-5.40) § <0.00
1 
 Platelets (109/L) 89 (55-139) 96 (61-176) 74 (56-123) # 0.188 
 Sodium (mmol/L) 137 (135-140) 136 (133-138) * 135 (132-139) * <0.00
1 
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 Bilirubin (mg/dL)  2.07 (1.07-4.24) 2.49 (1.06-4.43) 2.83 (1.50-10.30) * 0.012 
 Creatinine (mg/dL) 0.90 (0.74-1.30) 1.03 (0.78-1.44) 1.25 (0.88-1.85) § 0.001 
 Albumin (mg/dL) 3.2 (2.8-3.6) 3.0 (2.7-3.4) 3.1 (2.7-3.5) 0.081 
 INR 1.40 (1.22-1.59) 1.38 (1.25-1.68) 1.46 (1.28-1.73) 0.072 
 MAP (mmHg) 87 (78-93) 83 (77-96) 82 (75-90) 0.085 
 HR (bpm) 74 (65-83) 80 (70-90) * 80 (70-88) * <0.00
1 
Clinical data     
 Child-Pugh score 8 (7-10) 8 (7-10) 9 (8-11) § 0.028 
 Child-Pugh Class     
 Class A  84 (24) 25 (23) 7 (12) 0.088 
 Class B  159 (46) 55 (51) 30 (49) 0.619 
 Class C  104 (30) 28 (26) 24 (39) 0.186 
 MELD 15 (11-20) 16 (11-20) 21 (14-27) § 0.001 
 MELD-Na 16 (12-22) 19 (14-23) § 21 (17-30) § <0.00
1 
 CLIF-C-AD3 50 (45-57) 54 (50-64) * 54 (49-59) * <0.00
1 
 ACLF at admission 67 (19) 21 (19) 21 (34) 0.025 
 Grade 1  29 (43) 12 (57) 6 (29) 0.174 
 Grade 2  35 (52) 6 (30) 13 (62) 0.075 
 Grade 3  3 (4) 3 (14) 2 (9) 0.295 
 ACLF during 
hospitalization 
22 (6) 17 (16) 17 (28) <0.00
1 
 ACLF triggered by 
infection 
- 37 (97) 24 (63) <0.00
1 
Concomitant 
medications 
    
 PPI  223 (64) 74 (68) 43 (70) 0.518 
 Beta-blockers  151 (43) 47 (43) 26 (43) 0.991 
 Rifaximin 50 (14) 6 (6) 3 (5) 0.010 
 Quinolone 7 (2) 1 (1) 1 (2) 0.749 
Comorbidities     
 CCI 6.0 (5.0-7.4) 6.0 (4.8-7.4) 6.2 (4.4-7.4) 0.915 
 HCC 76 (22) 33 (30) 17 (29) 0.150 
 Diabetes (any stage)  122 (35) 39 (36) 19 (31) 0.795 
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*p<0.05 vs no bacterial infection; §p<0.05 vs all;  
MELD: model for end stage liver disease; ACLF: acute-on-chronic liver failure; CLIF-C: 
chronic liver failure consortium; AD: acute decompensation; CCI: Charlson Comorbidity 
Index; PPI: proton pump inhibitors; HCC: hepatocellular carcinoma. 
 
 
 
Characteristics of infections  
Bacterial infections were classified as community acquired in 69 (41%) cases, healthcare-
associated in 39 (23%) cases and hospital acquired in 61 (36%) cases. Pneumonia was the 
leading cause of infection (41, 24%), followed by primary BSIs (30, 17%), UTI (26, 15%) 
SBP (25, 15%), and SSTI (15, 9%). Primary BSI were more frequent among hospital 
acquired infection, while UTI and SST were more prevalent among infections diagnosed at 
admission (Table 17). 
 
Table 17. Source of infection according with epidemiological classification in the 169 patients 
with bacterial infection at hospital admission or during the hospital stay. 
SITE ALL 
INFECTIONS 
COMMUNITY 
ACQUIRED 
HEALTHCARE 
ASSOCIATED 
HOSPITAL 
ACQUIRED 
P 
n 169 (100) 69 (39%) 31 (23%) 61 (39%) - 
SBP 26 (15) 11 (16) 7 (18) 8 (13) 0.797 
BSI 30 (18) 4 (6) 5 (13) 21 (34) <0.001 
Pneumonia 41 (24) 16 (23) 15 (38) 10 (16) 0.041 
UTI 26 (15) 13 (19) 6 (15) 7 (11) 0.509 
IAI 18 (11) 5 (7) 3 (8) 10 (16) 0.191 
SSTI 15 (9) 11 (16) 3 (8) 1 (2) 0.016 
Other#  13 (8) 9 (13) 0 (0) 4 (7) 0.046 
# Other infection included 9 cases of biliary tract infection, 1 case of transjugular intrahepatic porto-systemic 
shunt infection, 1 case of bone and joint infection, 1 case of Ludwig’s angina,1 case of Clostridium difficile 
infection; *one case of Clostridium difficile; § one case of Legionella pneumophila.  
SBP: spontaneous bacterial peritonitis; BSI: bloodstream infection; UTI: Urinary tract infection; IAI: 
intrabdominal infection; SSTI: skin and soft tissue infection;   
ESBL: extended spectrum beta-lactamase; CRE: Carbapenem-resistant Enterobacteriaceae; MDR: multi drug 
resistant. 
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Regarding the severity of infection, the median SOFA score was 4 (3-7) and 25 (15%) 
patients had a qSOFA ≥ 2 points. Furthermore, 65 (38%) patients presented with sepsis and 
13 (8%) patients with septic shock. 
A microbiological diagnosis was obtained in 93 (55%) patients. The etiology of culture-
positive infection is reported in table 18.  
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Table 18. Etiology of 93 culture-positive bacterial infections collected among the 169 bacterial 
infections recorded during the study. Percentages refers to the total of culture-positive 
infection. 
  SBP Primary BSI Pneumonia UTI IAI SSTI Other# 
n 26 (28) 30 (32) 41 (44) 26 (28) 18 (19) 2 (2) 13 (14) 
Gram-positive cocci 1 (11) 9 (30) 4 (22) 4 (21) 3 (25) 1 (50) 3 (43) 
 Staphylococcus aureus 0 (0) 3 (10) 3 (17) 0 (0) 0 (0) 1 (50) 0 (0) 
 Enterococcus faecalis  0 (0) 1 (3) 1 (6) 3 (16) 3 (25) 0 (0) 0 (0) 
 Enterococcus faecium 1 (11) 2 (7) 0 (0) 1 (6) 0 (0) 0 (0) 2 (29) 
 CoNS 0 (0) 4 (13) 0 (0) 0 (0) 0 (0) 0 (0) 1 (14) 
 Other GP* 1 (11) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (14) 
Gram-negative bacilli 7 (78) 19 (63) 11 (68) 18 (78) 7 (11) 1 (50) 4 (50) 
    Enterobacteriacee 7 (78) 16 (53) 6 (35) 16 (84) 6 (54) ‘0 (0) 4 (50) 
       ESBL 2 (18) 3 (10) 2 (12) 6 (33) 3 (27) 0 (0) 1 (14) 
  CRE 0 (0) 3 (10) 0 (0) 2 (10) 4 (36) 0 (0) 0 (0) 
 Non-fermenting 0 (0) 5 (17) 4 (25) 0 (0) 1 (9) 1 (50) 0 (0) 
 Other GN§ 0 (0) 0 (0) 1 (6) 0 (0) 0 (0) 0 (0) 0 (0) 
MDR pathogens 4 (36) 19 (58) 6 (33) 10 (53) 4 (36) 1 (50) 3 (37) 
Fungi 1 (11) 2 (7) 0 (0) 0 (0) 1 (9) 0 (0) 1 (14) 
Polymicrobial 1 (11) 2 (7) 1 (6) 2 (11) 0 (0) 0 (0) 3 (47) 
Culture-negative  17 (65) 0 (0) 25 (61) 8 (30) 7 (39) 13 (87) 6 (46) 
Other infection included 9 cases of biliary tract infection, 1 case of transjugular intrahepatic porto-systemic 
shunt infection, 1 case of bone and joint infection, 1 case of Ludwig’s angina,1 case of Clostridium difficile 
infection; *one case of Clostridium difficile; § one case of Legionella pneumophila.  
SBP: spontaneous bacterial peritonitis; BSI: bloodstream infection; UTI: Urinary tract infection; IAI: 
intrabdominal infection; SSTI: skin and soft tissue infection; ESBL: extended spectrum beta-lactamase; CRE: 
Carbapenem-resistant enterobacteriaceae; MDR: multi drug resistant. 
 
 
 
Briefly, Gram-positive cocci were detected in 25 (27%) of cases, consisting mostly in 
Staphylococcus aureus (7, 7%), Enteroccocus faecalis (8, 9%), and Enterococcus faecium 
(6, 6%). Gram-negative bacteria were identified in 63 cases (67%). Of these, 
Enterobacteriaceae were identified in 54 (58%) cases, including Escherichia coli and 
Klebsiella pneumoniae in 33% and 14% of cases, respectively. Non-fermenting bacilli were 
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isolated in 12 out of 93 (13%) cases of culture-positive infections. Lastly, fungal infections 
were identified in 4% of cases. In all cases of fungal infection, Candida albicans was the 
causative pathogen. Overall, 40 (43%) pathogens were classified as MDR including 
extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae (19% of all 
isolates, 33% of Enterobacteriaceae) and carbapenem-resistant Enterobacteriaceae (CRE) 
(8% of all isolates, 14% of Enterobacteriaceae).  
Finally, culture-negative infections were mostly SSTI (13, 68%), pneumonia (27, 58%), and 
SBP (13, 54%).  
 
Comparison of infected patients complicated or not by ACLF 
Patients with bacterial infection were more prone to present ACLF (61/169 [41%] vs 89/347 
[26%], p<0.002) patients (Figure 7). Namely, a concomitant diagnosis of ACLF and infection 
was placed in 39 (64%) patients, while 21 (36%) patients developed ACLF after diagnosis 
of infection with a median delay of 8 (IQR: 2-17) days. Moreover, 15 patients presented 
ACLF before the development of a bacterial infection and therefore were excluded from the 
subsequent analysis. 
Table 19 shows the demographic and clinical characteristics of patients with or without ACLF 
at the time of infection diagnosis. Patients with infection-related ACLF were more likely to 
have alcohol-related cirrhosis (31% vs 17%, p=0.04), MELD (23 [18-30] vs 13 [10-17], 
p<0.001) scores at admission.  
Regarding the characteristics of bacterial infections (Table 19), patients with ACLF had more 
frequently hospital-acquired infections (39% vs 25%, p<0.001), healthcare related infections 
(36% vs 19%, p=0.02), bloodstream infection (BSI) including primary BSI (26% vs 11% 
p=0.01) or any bacteremic infection (46% vs 14%, p<0.001).Furthermore, the prevalence of 
MDR bacteria was significantly higher in patients with ACLF compared to patients with 
uncomplicated bacterial infection (37% vs 13%, p<0.001). Overall, the severity of bacterial 
infections in patients with ACLF was significantly higher than in patients without ACLF. 
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Table 19. Demographic, clinical and microbiological characteristics of patients with bacterial 
infection complicated or not by ACLF. 
  UNCOMPLICATED 
INFECTIONS 
INFECTION 
COMPLICATED BY 
ACLF 
P 
 N 93 61  
Demographic data    
 Age (years) 64 ± 13 62 ± 13 0.319 
 Sex (male) 60 (65) 39 (64) 0.941 
Etiology of cirrhosis1    
 Viral 47 (50) 24 (39) 0.173 
 Alcohol 16 (17) 19 (31) 0.043 
 NASH 7 (7) 5 (8) 1.000 
 Viral and alcohol 6 (6) 2 (3) 0.480 
 Viral and NASH 1 (1) 1 (1) 1.000 
 Alcohol and NASH 0 (0) 3 (5) 0.060 
 Other 16 (17) 10 (16) 0.895 
Clinical data    
 MELD score  14 (10-17) 23 (18-30) <0.001 
Comorbidities    
 Diabetes 32 (34) 23 (37) 0.67 
 Chronic renal failure 9 (10) 11 (18) 0.13 
 HCC 29 (31) 17 (28) 0.66 
 CCI 6.2 (4.8-7.35) 6.1 (4.7-7.3)  
Admission diagnosis    
 Ascites 34 (37) 34 (56) 0.02 
 Hepatic encephalopathy 10 (11) 19 (31) 0.002 
 Bleeding 4 (4) 2 (3) 1 
 Worsening of liver function 6 (6) 9 (14) 0.09 
 Suspected infection 62 (67) 32 (52) 0.07 
Infection classification    
 Community acquired 51 (55) 16 (21) <0.001 
 Hospital acquired 23 (25) 24 (39) 0.05 
 Healthcare associated 18 (19) 22 (36) 0.02 
Infection severity    
 qSOFA 0 (0-0) 1 (0-2) <0.001 
 qSOFA≥2  3 (3) 16 (29) <0.001 
 SOFA 3 (0-6) 7 (4-9) <0.001 
 Septic shock 0 (0) 15 (18) <0.001 
Infection source    
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 Pneumonia  22 (24) 17 (22) 0.83 
 Primary bloodstream infection  10 (11) 16 (26) 0.01 
 SBP 12 (13) 9 (15) 0.74 
 Urinary tract 20 (21) 6 (10) 0.06 
 SSTI 11 (12) 4 (6) 0.28 
 Bacteriemic infection  13 (14) 28 (46) <0.001 
Bacteria    
 GNB 28 (30) 29 (47) 0.03 
 GPC  9 (10) 15 (20) 0.06 
 Staphylococcus aureus  5 (5) 2 (3) 0.46 
 Enteroccus faecalis 3 (3) 5 (6) 0.47 
 Enterococcus faecium  1 (1) 5 (6) 0.09 
Fungi    
 Candida spp  1 (1) 3 (5) 0.30 
Microbiological features    
 Polimicrobial  5 (5) 8 (9) 0.05 
 Negative cultures 51 (51) 23 (29) 0.003 
 Any MDR bacteria  12 (13) 23 (37) <0.001 
MELD: model for end stage liver disease; ACLF: acute-on-chronic liver failure; CLIF-C: chronic liver 
failure consortium; AD: acute decompensation; CCI: Charlson Comorbidity Index; PPI: proton pump 
inhibitors; HCC: hepatocellular carcinoma; SBP: spontaneous bacterial peritonitis; BSI: bloodstream 
infection; UTI: Urinary tract infection; IAI: intrabdominal infection; SSTI: skin and soft tissue infection; 
SOFA sequential organ failure assessment; ESBL extended spectrum beta-lactamase; CR 
carbapenem resistant; MDR multidrug-resistant; GNB Gram-negative bacilli; GPC Gram-positive 
cocci. 
 
 
At multivariate analysis, the factors independently associated with ACLF were MELD-Na 
score [OR 1.17 (95% CI: 1.07-1.27), p=0.004], bacteremic infection [OR 4.59 (95% CI: 1.64-
12.28), p=0.004], infection caused by a MDR pathogen [OR 2.88 (95% CI: 1.01- 8.20), 
p=0.048] and having a quickSOFA score ≥ 2 points [OR 9.39 (95% CI: 2.04-43.28) p=0.004].  
(Table 20).  
 
 
 
Table 20. Multivariate logistic regression analysis of factors associated to the 
development of acute-on-chronic liver failure (ACLF) in patients with bacterial 
infection.  
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Covariate Odds ratio 95% CI P 
Bacteremic infection  4.59 1.64 – 12.18 0.004 
MELD-Na score (1-point increase) 1.17 1.07 – 1.27 0.001 
QuickSOFA ≥2 points  9.39 2.04 - 43.28 0.004 
Infection caused by a MDR pathogen 2.88 1.01-8.20 0.048 
The model calibration was assessed with Hosmer-Lemeshow goodness-of-fit test which showed a P value 
0.71. The area under the receiver operating characteristic curve assessing the discriminatory power of the 
model was 0.88 (95% CI 0.82-0.93). Other variables included in the model were healthcare associated 
infection, urinary tract infections, alcoholic cirrhosis, ascites at hospital admission. 
MELD: model for end stage liver disease; SOFA sequential organ failure assessment; MDR multidrug-
resistant. 
 
 
 
Finally, in patients with infection (169 cases), we sought differences between those 
developing delayed ACLF (21 cases) and patients never developing ACLF. Patients with 
delayed ACLF were more likely to have pneumonia (52% vs 24%, p=0.009), bacteremic 
infection (53% vs 15%, p=0.003), infection caused by a ESBL-producing 
Enterobacteriaceae (33% vs 4%, p<0.001) or any MDR (43% vs 13% p=0.001), and did not 
receive adequate empirical treatment in the first 24 hours (73% vs 0%, p=0.008). Lastly, in 
this group of patients UTI were less frequent than patients without ACLF (0% vs 20%, 
p=0.01).  
 
Survival    
After 1-year of follow-up of the 516 patients included in the analysis, 14 (3%) patients were 
lost to follow-up and 53 patients (10%) underwent liver transplantation. Overall 189 (37%) 
patients died after a median (IQR) time of 90 (32-207) days from the study inclusion. 
Differences among survivors and non-survivors after 1-year of follow up are depicted in table 
21 
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Table 21. Demographic, biochemical and clinical characteristics of survivors and non-
survivors after 1-year follow-up.  
  SURVIVORS NON-SURVIVORS P 
 N 313 189  
Anthropometric data    
 Age (years) 59 (50-69) 66 (57-76) <0.001 
 Male sex 202 (64) 111 (59) 0.217 
Etiology of cirrhosis1    
 Viral 119 (38) 90 (48) 0.035 
 Alcohol 67 (21) 39 (21) 0.830 
 NASH 23 (7) 9 (5) 0.346 
 Viral and alcohol 42 (13) 13 (7) 0.023 
 Viral and NASH 7 (2) 6 (3) 0.568 
 Alcohol and NASH 6 (2) 4 (2) 1.000 
 Other 54 (17) 32 (17) 0.926 
AD at admission    
 Ascites 119 (38) 99 (52) 0.002 
 HE 73 (23) 62 (33) 0.020 
 Liver failure 35 (11) 33 (17) 0.046 
 Renal failure 17 (5) 19 (10) 0.052 
 GI bleeding 29 (9) 6 (3) 0.011 
 Bacterial Infection 59 (19) 49 (26) 0.062 
 Any bacterial infection 88 (28) 81 (43) 0.001 
Biochemical and hemodynamic data   
 WBC (109/L) 5.2 (3.5-8.0) 6.1 (4.1-9.3) 0.003 
 CRP (mg/dL) 0.94 (0.32-2.35) 1.63 (0.81-5.27) <0.001 
 Platelets (109/L) 89 (57-143) 87 (55-139) 0.786 
 Sodium (mmol/L) 137 (134-140) 136 (133-139) 0.004 
 Bilirubin (mg/dL)  1.92 (0.94-3.66) 2.94 (1.48-6.10) <0.001 
 Creatinine (mg/dL) 0.90 (0.72-1.24) 1.11 (0.82-1.53) <0.001 
 Albumin (mg/dL) 3.2 (2.9-3.7) 3.0 (2.7-3.4) <0.001 
 INR 1.36 (1.22-1.56) 1.46 (1.27-1.70) 0.001 
 MAP (mmHg) 87 (78-93) 83 (77-92) 0.004 
 HR (bpm) 75 (66-85) 78 (68-86) 0.194 
Clinical data    
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 Child-Pugh score 8 (6-9) 9 (8-11) <0.001 
 Child-Pugh Class    
 Class A  84 (24) 25 (23) 0.088 
 Class B  159 (46) 55 (51) 0.619 
 Class C  104 (30) 28 (26) 0.186 
 MELD 14 (10-18) 17 (14-24) <0.001 
 MELD-Na 16 (12-21) 20 (15-26) <0.001 
 CLIF-C-AD3 49 (43-55) 55 (50-62) <0.001 
 Any ACLF 71 (23) 92 (49) <0.001 
 Grade 1  45 (14) 40 (21)  
 Grade 2  22 (7) 38 (20) <0.001 
 Grade 3  4 (1) 13 (7)  
Comorbidities    
 Charlson Comorbidity Index (CCI) 5.5 (4.4-6.9) 6.8 (5.7-8.6) <0.001 
 HCC 58 (18) 55 (29) 0.006 
 Diabetes (any stage)  104 (33) 74 (39) 0.179 
 
AD: acute decompensation; MELD: model for end stage liver disease; ACLF: acute-on-
chronic liver failure; CLIF- C: chronic liver failure consortium; AD: acute decompensation; 
COPD: chronic obstructive pulmonary disease; PPI: proton pump inhibitors; WBC: white 
blood cells; INR: international normalized ratio; CRP: C-reactive protein; HCC: 
hepatocellular carcinoma. 
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Overall, bacterial or fungal infections were associated to a worse 1-year survival as 
compared to patients without bacterial infection (50 vs 65%, p=0.001). Interestingly, the 
Kaplan Meier survival analysis showed that 1-year survival was similar in infected and non-
infected patients without ACLF (71% vs 67% p=0.337), while bacterial infections 
complicated by ACLF were associated to a significantly lower survival rate than ACLF 
precipitated by other events (23 vs 47%, p=0.010). To further evaluate the impact of ACLF 
and bacterial or fungal infections complicated or non-complicated by ACLF on 1-year 
survival we first analyzed the accuracy of 4 cirrhosis-specific scores (MELD, MELD-Na, 
Child-Pugh and CLIFc-AD score) and Charlson Comorbidity Index in predicting 1-year 
mortality using ROC curves. Both Charlson Comorbidity Index [AUROC 0.70 (95% CI 0.65-
0.74)] and CLIFc-AD [AUROC 0.70 (95% CI 0.65-0.74) best predicted 1-year mortality. 
Therefore, the final Cox regression model for 1-year mortality included CCI and CLIFc-AD 
score as continuous variables. Uncomplicated bacterial infection was not associated with an 
increased risk of mortality after 1 year [AHR 0.84 (95% CI 0.53-1.33) p<0.481]. Conversely, 
ACLF triggered by infection [AHR 3.14 (95% CI 2.10-4.69) p<0.001 were independent 
predictors of mortality.    
 
 
DISCUSSION 
In this prospective study, we aimed to identify cirrhotic patients with bacterial infection at 
higher risk of ACLF and we compared the long-term mortality of patients according with the 
presence of ACLF and/or bacterial infections. The main findings are that patients with  
bacteriemic, infections or caused by MDR pathogens are at high risk to develop ACLF.  In 
addition, our results indicate that bacterial infections do not change the natural history of 
cirrhosis unless they are associated by ACLF.   
To date few studies evaluated risk factors for ACLF in patients admitted with acute 
decompensation and there is a lack of data regarding the main subtype of bacterial infection 
associated with this syndrome. This aspect seems of pivotal importance as the bacterial 
infection are the main cause of ACLF.  
In the study of Fernandez et al.(84) based on a multicenter enrollment, patients with bacterial 
infections associated with ACLF were compared with patients with AD. Like in our study, 
patients with ACLF were characterized by severe infections, nosocomial infections and 
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isolation of a MDR pathogen. They also found that SBP and pneumonia were more likely to 
be associated to ACLF. Our results are partially in contradiction with this report. Particularly, 
even if pneumonia was associated with delayed ALCF we did not find any association 
between SBP and ACLF.  The possible explanations are several. First, the epidemiology of 
infection may be different in our settings. In fact, the overall rate of SBP were lower than 
previous reports but similar to that of recent Italian studies(9, 20, 21). Second, management 
and prevention of cirrhosis complication may have been different, including the rate of 
patients in antibiotic prophylaxis or in treatment with albumin.  Finally, the definitions of 
infection were slightly different and, in addition, in our study every case of infection was 
reviewed by a team of infectious disease consultants and hepatologists. In our study 
bacteremic infection, infection caused by MDR were independent risk factors for ACLF 
whereas urinary tract infections were found to have a lower propensity to ACLF. This latter 
aspect may be controversial. A previous study in cirrhotic patients found that UTI, 
gastrointestinal infection and SBP were characterized by higher incidence of renal failure 
(85). On the other hand, studies with a population that included also non-cirrhotic patients 
found that UTI are associated with a lower mortality rate, even if caused by MDR pathogens. 
(86, 87). Bacteremic infection and infections caused by MDR have already demonstrated to 
be associated with worse outcome if compared with other source and etiology of infection(9, 
31, 58). Thus, it is not surprising that they have an impact also in determining the risk of 
ACLF.    
Another important finding of our study is that bacterial infection itself is not a marker of poor 
prognosis. The hallmark of bacterial infection as an event that change the history of the 
disease is due to several previous studies.(8, 19, 88). However, none of the studies stratified 
patients for the presence of ACLF.  According with our finding, bacterial infection accelerates 
the course of the disease only if complicated by ACLF. However, patients with ACLF 
precipitated by infection exhibited worse prognosis when compared with patients with non-
infectious ACLF.  
If our data will be furtherly confirmed, new criteria may be proposed to differentiate cirrhotic 
patients with complicated bacterial infection including those with bacteremic infection, non-
UTI or those presenting with ACLF. This new classification may be useful to prioritize the 
medical treatment, select patients who may benefit form a broader spectrum antibiotic 
therapy and prioritize transplantation evaluation. In fact, in patients with ACLF and bacterial 
infections the 30,90,180 and 365-day mortality was 32%, 40%, 48% and 54% of cases, 
respectively.  
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Our study has some limitations. First, most patients were enrolled in a large university 
teaching hospital with a transplant center. This may have selected patients with advanced 
liver disease. Therefore, we found a lower rate of SBP than reported by other studies(4, 17). 
Second, due to Italian laws informed consent for participation in the study cannot be given 
in case of unconsciousness. Thus, several ICU patients were not included in the study.     
Notwithstanding these limitations, we believe that our study can give some novel and robust 
information on bacterial infection in cirrhotic patients, identifying risk factors for ACLF and 
consequently for long-term prognosis.  
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CONCLUSION  
 
 
In this work several aspects of patients with ESLD were evaluated. The main findings may 
be summarized as follows:  
- Infection remain a worthy cause of morbidity and mortality of patients with ESLD. 
Among all patients admitted for an acute decompensation 32% develop a bacterial 
or fungal infection.  
- Bloodstream infections (BSI) are an important cause of infection. Among all source 
of infection, primary BSI occurs in 18% of all patients and in 34% of patients with 
nosocomial infection. Moreover, bacteremic infections (one third of infections) are 
independently associated to ACLF. 
- In Europe 31% of BSI are caused by MDR pathogens with a wide difference between 
countries. Isolation of a MDR pathogen is associated to a significative high risk of 
failure of first-line empiric treatment.  
- Different causative pathogens of BSI are found in patient with alcoholic liver disease 
when compared with other etiology of cirrhosis. In patients with alcoholic cirrhosis a 
significant high prevalence of Gram-positive cocci was found.  
- Despite previous studies our results indicate that bacterial infection changes the 
course of cirrhosis only when complicated by ACLF. Patients with bacterial infection 
without ACLF have a similar prognosis of patients with other cause of acute 
decompensation. However, patients with ACLF caused by infection show a higher 
mortality after 1 year of follow-up.   
- Among patients with BSI, appropriated empirical treatment in the first 24h from 
diagnosis of infection is associated to improved survival. In addition, continuous or 
extended infusion of beta-lactams seems more effective than intermittent 
administration, especially when administered empirically.          
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